<html>

<head>
<meta http-equiv=Content-Type content="text/html; charset=windows-1252">
<meta name=Generator content="Microsoft Word 15 (filtered)">
<title>Armisarte R-22 PI - clean</title>
<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:Helvetica;
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:Wingdings;
	panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"MS Mincho";
	panose-1:2 2 6 9 4 2 5 8 3 4;}
@font-face
	{font-family:"Cambria Math";
	panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
	{font-family:Calibri;
	panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
	{font-family:Verdana;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:Tahoma;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:Consolas;
	panose-1:2 11 6 9 2 2 4 3 2 4;}
@font-face
	{font-family:"Malgun Gothic";
	panose-1:2 11 5 3 2 0 0 2 0 4;}
@font-face
	{font-family:"\@Malgun Gothic";}
@font-face
	{font-family:"\@MS Mincho";
	panose-1:2 2 6 9 4 2 5 8 3 4;}
@font-face
	{font-family:Times-Roman;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
h1
	{mso-style-link:"Heading 1 Char";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:17.85pt;
	text-indent:-17.85pt;
	line-height:13.0pt;
	font-size:13.0pt;
	font-family:"Times New Roman",serif;
	text-transform:uppercase;
	font-weight:bold;}
h2
	{mso-style-link:"Heading 2 Char";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Helvetica",sans-serif;
	font-weight:bold;
	font-style:italic;}
h3
	{mso-style-link:"Heading 3 Char";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:4.0pt;
	margin-left:0in;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
h4
	{mso-style-link:"Heading 4 Char";
	margin:0in;
	text-align:justify;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
h5
	{mso-style-link:"Heading 5 Char";
	margin:0in;
	text-align:justify;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:normal;}
h6
	{mso-style-link:"Heading 6 Char";
	margin:0in;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:normal;
	font-style:italic;}
p.MsoHeading7, li.MsoHeading7, div.MsoHeading7
	{mso-style-link:"Heading 7 Char";
	margin:0in;
	text-align:justify;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-style:italic;}
p.MsoHeading8, li.MsoHeading8, div.MsoHeading8
	{mso-style-link:"Heading 8 Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.35pt;
	text-align:justify;
	text-indent:-28.35pt;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;
	font-style:italic;}
p.MsoHeading9, li.MsoHeading9, div.MsoHeading9
	{mso-style-link:"Heading 9 Char";
	margin:0in;
	text-align:justify;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;
	font-style:italic;}
p.MsoIndex1, li.MsoIndex1, div.MsoIndex1
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:11.0pt;
	text-indent:-11.0pt;
	line-height:normal;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex2, li.MsoIndex2, div.MsoIndex2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:22.0pt;
	text-indent:-11.0pt;
	line-height:normal;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex3, li.MsoIndex3, div.MsoIndex3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:33.0pt;
	text-indent:-11.0pt;
	line-height:normal;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex4, li.MsoIndex4, div.MsoIndex4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:44.0pt;
	text-indent:-11.0pt;
	line-height:normal;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex5, li.MsoIndex5, div.MsoIndex5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:55.0pt;
	text-indent:-11.0pt;
	line-height:normal;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex6, li.MsoIndex6, div.MsoIndex6
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:66.0pt;
	text-indent:-11.0pt;
	line-height:normal;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex7, li.MsoIndex7, div.MsoIndex7
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:77.0pt;
	text-indent:-11.0pt;
	line-height:normal;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex8, li.MsoIndex8, div.MsoIndex8
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:88.0pt;
	text-indent:-11.0pt;
	line-height:normal;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex9, li.MsoIndex9, div.MsoIndex9
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:99.0pt;
	text-indent:-11.0pt;
	line-height:normal;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc1, li.MsoToc1, div.MsoToc1
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:5.0pt;
	margin-left:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc2, li.MsoToc2, div.MsoToc2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:5.0pt;
	margin-left:11.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc3, li.MsoToc3, div.MsoToc3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:5.0pt;
	margin-left:22.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc4, li.MsoToc4, div.MsoToc4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:5.0pt;
	margin-left:33.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc5, li.MsoToc5, div.MsoToc5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:5.0pt;
	margin-left:44.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc6, li.MsoToc6, div.MsoToc6
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:5.0pt;
	margin-left:55.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc7, li.MsoToc7, div.MsoToc7
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:5.0pt;
	margin-left:66.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc8, li.MsoToc8, div.MsoToc8
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:5.0pt;
	margin-left:77.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc9, li.MsoToc9, div.MsoToc9
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:5.0pt;
	margin-left:88.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoNormalIndent, li.MsoNormalIndent, div.MsoNormalIndent
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:35.4pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoFootnoteText, li.MsoFootnoteText, div.MsoFootnoteText
	{mso-style-link:"Footnote Text Char";
	margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.MsoCommentText, li.MsoCommentText, div.MsoCommentText
	{mso-style-link:"Comment Text Char";
	margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.MsoHeader, li.MsoHeader, div.MsoHeader
	{mso-style-link:"Header Char";
	margin:0in;
	line-height:normal;
	font-size:10.0pt;
	font-family:"Helvetica",sans-serif;}
p.MsoFooter, li.MsoFooter, div.MsoFooter
	{mso-style-link:"Footer Char";
	margin:0in;
	line-height:normal;
	font-size:8.0pt;
	font-family:"Helvetica",sans-serif;}
p.MsoIndexHeading, li.MsoIndexHeading, div.MsoIndexHeading
	{margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Cambria",serif;
	font-weight:bold;}
p.MsoCaption, li.MsoCaption, div.MsoCaption
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:10.0pt;
	margin-left:0in;
	line-height:normal;
	font-size:9.0pt;
	font-family:"Times New Roman",serif;
	color:#4F81BD;
	font-weight:bold;}
p.MsoTof, li.MsoTof, div.MsoTof
	{margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoEnvelopeAddress, li.MsoEnvelopeAddress, div.MsoEnvelopeAddress
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.05pt;
	line-height:normal;
	font-size:12.0pt;
	font-family:"Cambria",serif;}
p.MsoEnvelopeReturn, li.MsoEnvelopeReturn, div.MsoEnvelopeReturn
	{margin:0in;
	line-height:normal;
	font-size:10.0pt;
	font-family:"Cambria",serif;}
span.MsoFootnoteReference
	{vertical-align:super;}
p.MsoEndnoteText, li.MsoEndnoteText, div.MsoEndnoteText
	{mso-style-link:"Endnote Text Char";
	margin:0in;
	line-height:normal;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToa, li.MsoToa, div.MsoToa
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:11.0pt;
	text-indent:-11.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoMacroText, li.MsoMacroText, div.MsoMacroText
	{mso-style-link:"Macro Text Char";
	margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:Consolas;}
p.MsoToaHeading, li.MsoToaHeading, div.MsoToaHeading
	{margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	line-height:13.0pt;
	font-size:12.0pt;
	font-family:"Cambria",serif;
	font-weight:bold;}
p.MsoList, li.MsoList, div.MsoList
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:14.15pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListCxSpFirst, li.MsoListCxSpFirst, div.MsoListCxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:14.15pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListCxSpMiddle, li.MsoListCxSpMiddle, div.MsoListCxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:14.15pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListCxSpLast, li.MsoListCxSpLast, div.MsoListCxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:14.15pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet, li.MsoListBullet, div.MsoListBullet
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBulletCxSpFirst, li.MsoListBulletCxSpFirst, div.MsoListBulletCxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBulletCxSpMiddle, li.MsoListBulletCxSpMiddle, div.MsoListBulletCxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBulletCxSpLast, li.MsoListBulletCxSpLast, div.MsoListBulletCxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber, li.MsoListNumber, div.MsoListNumber
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumberCxSpFirst, li.MsoListNumberCxSpFirst, div.MsoListNumberCxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumberCxSpMiddle, li.MsoListNumberCxSpMiddle, div.MsoListNumberCxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumberCxSpLast, li.MsoListNumberCxSpLast, div.MsoListNumberCxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList2, li.MsoList2, div.MsoList2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.3pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList2CxSpFirst, li.MsoList2CxSpFirst, div.MsoList2CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.3pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList2CxSpMiddle, li.MsoList2CxSpMiddle, div.MsoList2CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.3pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList2CxSpLast, li.MsoList2CxSpLast, div.MsoList2CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.3pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList3, li.MsoList3, div.MsoList3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:42.45pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList3CxSpFirst, li.MsoList3CxSpFirst, div.MsoList3CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:42.45pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList3CxSpMiddle, li.MsoList3CxSpMiddle, div.MsoList3CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:42.45pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList3CxSpLast, li.MsoList3CxSpLast, div.MsoList3CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:42.45pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList4, li.MsoList4, div.MsoList4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:56.6pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList4CxSpFirst, li.MsoList4CxSpFirst, div.MsoList4CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:56.6pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList4CxSpMiddle, li.MsoList4CxSpMiddle, div.MsoList4CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:56.6pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList4CxSpLast, li.MsoList4CxSpLast, div.MsoList4CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:56.6pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList5, li.MsoList5, div.MsoList5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:70.75pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList5CxSpFirst, li.MsoList5CxSpFirst, div.MsoList5CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:70.75pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList5CxSpMiddle, li.MsoList5CxSpMiddle, div.MsoList5CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:70.75pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList5CxSpLast, li.MsoList5CxSpLast, div.MsoList5CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:70.75pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet2, li.MsoListBullet2, div.MsoListBullet2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:32.15pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet2CxSpFirst, li.MsoListBullet2CxSpFirst, div.MsoListBullet2CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:32.15pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet2CxSpMiddle, li.MsoListBullet2CxSpMiddle, div.MsoListBullet2CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:32.15pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet2CxSpLast, li.MsoListBullet2CxSpLast, div.MsoListBullet2CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:32.15pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet3, li.MsoListBullet3, div.MsoListBullet3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:46.3pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet3CxSpFirst, li.MsoListBullet3CxSpFirst, div.MsoListBullet3CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:46.3pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet3CxSpMiddle, li.MsoListBullet3CxSpMiddle, div.MsoListBullet3CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:46.3pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet3CxSpLast, li.MsoListBullet3CxSpLast, div.MsoListBullet3CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:46.3pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet4, li.MsoListBullet4, div.MsoListBullet4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:60.45pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet4CxSpFirst, li.MsoListBullet4CxSpFirst, div.MsoListBullet4CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:60.45pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet4CxSpMiddle, li.MsoListBullet4CxSpMiddle, div.MsoListBullet4CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:60.45pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet4CxSpLast, li.MsoListBullet4CxSpLast, div.MsoListBullet4CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:60.45pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet5, li.MsoListBullet5, div.MsoListBullet5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:74.6pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet5CxSpFirst, li.MsoListBullet5CxSpFirst, div.MsoListBullet5CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:74.6pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet5CxSpMiddle, li.MsoListBullet5CxSpMiddle, div.MsoListBullet5CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:74.6pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet5CxSpLast, li.MsoListBullet5CxSpLast, div.MsoListBullet5CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:74.6pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber2, li.MsoListNumber2, div.MsoListNumber2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:32.15pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber2CxSpFirst, li.MsoListNumber2CxSpFirst, div.MsoListNumber2CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:32.15pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber2CxSpMiddle, li.MsoListNumber2CxSpMiddle, div.MsoListNumber2CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:32.15pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber2CxSpLast, li.MsoListNumber2CxSpLast, div.MsoListNumber2CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:32.15pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber3, li.MsoListNumber3, div.MsoListNumber3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:46.3pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber3CxSpFirst, li.MsoListNumber3CxSpFirst, div.MsoListNumber3CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:46.3pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber3CxSpMiddle, li.MsoListNumber3CxSpMiddle, div.MsoListNumber3CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:46.3pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber3CxSpLast, li.MsoListNumber3CxSpLast, div.MsoListNumber3CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:46.3pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber4, li.MsoListNumber4, div.MsoListNumber4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:60.45pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber4CxSpFirst, li.MsoListNumber4CxSpFirst, div.MsoListNumber4CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:60.45pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber4CxSpMiddle, li.MsoListNumber4CxSpMiddle, div.MsoListNumber4CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:60.45pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber4CxSpLast, li.MsoListNumber4CxSpLast, div.MsoListNumber4CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:60.45pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber5, li.MsoListNumber5, div.MsoListNumber5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:74.6pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber5CxSpFirst, li.MsoListNumber5CxSpFirst, div.MsoListNumber5CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:74.6pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber5CxSpMiddle, li.MsoListNumber5CxSpMiddle, div.MsoListNumber5CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:74.6pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber5CxSpLast, li.MsoListNumber5CxSpLast, div.MsoListNumber5CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:74.6pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoTitle, li.MsoTitle, div.MsoTitle
	{mso-style-link:"Title Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:15.0pt;
	margin-left:0in;
	line-height:normal;
	border:none;
	padding:0in;
	font-size:26.0pt;
	font-family:"Cambria",serif;
	color:#17365D;
	letter-spacing:.25pt;}
p.MsoTitleCxSpFirst, li.MsoTitleCxSpFirst, div.MsoTitleCxSpFirst
	{mso-style-link:"Title Char";
	margin:0in;
	margin-bottom:.0001pt;
	line-height:normal;
	border:none;
	padding:0in;
	font-size:26.0pt;
	font-family:"Cambria",serif;
	color:#17365D;
	letter-spacing:.25pt;}
p.MsoTitleCxSpMiddle, li.MsoTitleCxSpMiddle, div.MsoTitleCxSpMiddle
	{mso-style-link:"Title Char";
	margin:0in;
	margin-bottom:.0001pt;
	line-height:normal;
	border:none;
	padding:0in;
	font-size:26.0pt;
	font-family:"Cambria",serif;
	color:#17365D;
	letter-spacing:.25pt;}
p.MsoTitleCxSpLast, li.MsoTitleCxSpLast, div.MsoTitleCxSpLast
	{mso-style-link:"Title Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:15.0pt;
	margin-left:0in;
	line-height:normal;
	border:none;
	padding:0in;
	font-size:26.0pt;
	font-family:"Cambria",serif;
	color:#17365D;
	letter-spacing:.25pt;}
p.MsoClosing, li.MsoClosing, div.MsoClosing
	{mso-style-link:"Closing Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:212.6pt;
	line-height:normal;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoSignature, li.MsoSignature, div.MsoSignature
	{mso-style-link:"Signature Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:212.6pt;
	line-height:normal;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyText, li.MsoBodyText, div.MsoBodyText
	{mso-style-link:"Body Text Char";
	margin:0in;
	line-height:normal;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:green;
	font-style:italic;}
p.MsoBodyTextIndent, li.MsoBodyTextIndent, div.MsoBodyTextIndent
	{mso-style-link:"Body Text Indent Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	text-align:justify;
	line-height:normal;
	text-autospace:none;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue, li.MsoListContinue, div.MsoListContinue
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinueCxSpFirst, li.MsoListContinueCxSpFirst, div.MsoListContinueCxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:14.15pt;
	margin-bottom:.0001pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinueCxSpMiddle, li.MsoListContinueCxSpMiddle, div.MsoListContinueCxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:14.15pt;
	margin-bottom:.0001pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinueCxSpLast, li.MsoListContinueCxSpLast, div.MsoListContinueCxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue2, li.MsoListContinue2, div.MsoListContinue2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:28.3pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue2CxSpFirst, li.MsoListContinue2CxSpFirst, div.MsoListContinue2CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.3pt;
	margin-bottom:.0001pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue2CxSpMiddle, li.MsoListContinue2CxSpMiddle, div.MsoListContinue2CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.3pt;
	margin-bottom:.0001pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue2CxSpLast, li.MsoListContinue2CxSpLast, div.MsoListContinue2CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:28.3pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue3, li.MsoListContinue3, div.MsoListContinue3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:42.45pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue3CxSpFirst, li.MsoListContinue3CxSpFirst, div.MsoListContinue3CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:42.45pt;
	margin-bottom:.0001pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue3CxSpMiddle, li.MsoListContinue3CxSpMiddle, div.MsoListContinue3CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:42.45pt;
	margin-bottom:.0001pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue3CxSpLast, li.MsoListContinue3CxSpLast, div.MsoListContinue3CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:42.45pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue4, li.MsoListContinue4, div.MsoListContinue4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:56.6pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue4CxSpFirst, li.MsoListContinue4CxSpFirst, div.MsoListContinue4CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:56.6pt;
	margin-bottom:.0001pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue4CxSpMiddle, li.MsoListContinue4CxSpMiddle, div.MsoListContinue4CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:56.6pt;
	margin-bottom:.0001pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue4CxSpLast, li.MsoListContinue4CxSpLast, div.MsoListContinue4CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:56.6pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue5, li.MsoListContinue5, div.MsoListContinue5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:70.75pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue5CxSpFirst, li.MsoListContinue5CxSpFirst, div.MsoListContinue5CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:70.75pt;
	margin-bottom:.0001pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue5CxSpMiddle, li.MsoListContinue5CxSpMiddle, div.MsoListContinue5CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:70.75pt;
	margin-bottom:.0001pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue5CxSpLast, li.MsoListContinue5CxSpLast, div.MsoListContinue5CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:70.75pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoMessageHeader, li.MsoMessageHeader, div.MsoMessageHeader
	{mso-style-link:"Message Header Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:56.7pt;
	text-indent:-56.7pt;
	line-height:normal;
	background:#CCCCCC;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Cambria",serif;}
p.MsoSubtitle, li.MsoSubtitle, div.MsoSubtitle
	{mso-style-link:"Subtitle Char";
	margin:0in;
	line-height:13.0pt;
	font-size:12.0pt;
	font-family:"Cambria",serif;
	color:#4F81BD;
	letter-spacing:.75pt;
	font-style:italic;}
p.MsoSalutation, li.MsoSalutation, div.MsoSalutation
	{mso-style-link:"Salutation Char";
	margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoDate, li.MsoDate, div.MsoDate
	{mso-style-link:"Date Char";
	margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyTextFirstIndent, li.MsoBodyTextFirstIndent, div.MsoBodyTextFirstIndent
	{mso-style-link:"Body Text First Indent Char";
	margin:0in;
	text-indent:.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyTextFirstIndent2, li.MsoBodyTextFirstIndent2, div.MsoBodyTextFirstIndent2
	{mso-style-link:"Body Text First Indent 2 Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoNoteHeading, li.MsoNoteHeading, div.MsoNoteHeading
	{mso-style-link:"Note Heading Char";
	margin:0in;
	line-height:normal;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyText2, li.MsoBodyText2, div.MsoBodyText2
	{mso-style-link:"Body Text 2 Char";
	margin:0in;
	text-align:justify;
	line-height:13.0pt;
	text-autospace:none;
	border:none;
	padding:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:blue;
	font-weight:bold;
	text-decoration:underline;}
p.MsoBodyText3, li.MsoBodyText3, div.MsoBodyText3
	{mso-style-link:"Body Text 3 Char";
	margin:0in;
	text-align:justify;
	line-height:normal;
	text-autospace:none;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:blue;}
p.MsoBodyTextIndent2, li.MsoBodyTextIndent2, div.MsoBodyTextIndent2
	{mso-style-link:"Body Text Indent 2 Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:56.7pt;
	text-align:justify;
	line-height:13.0pt;
	text-autospace:none;
	border:none;
	padding:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:blue;
	font-weight:bold;}
p.MsoBodyTextIndent3, li.MsoBodyTextIndent3, div.MsoBodyTextIndent3
	{mso-style-link:"Body Text Indent 3 Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:31.65pt;
	text-align:justify;
	line-height:13.0pt;
	text-autospace:none;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBlockText, li.MsoBlockText, div.MsoBlockText
	{margin-top:0in;
	margin-right:.8in;
	margin-bottom:0in;
	margin-left:.8in;
	line-height:13.0pt;
	border:none;
	padding:0in;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;
	color:#4F81BD;
	font-style:italic;}
a:link, span.MsoHyperlink
	{color:blue;
	text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
	{color:purple;
	text-decoration:underline;}
p.MsoDocumentMap, li.MsoDocumentMap, div.MsoDocumentMap
	{mso-style-link:"Document Map Char";
	margin:0in;
	line-height:13.0pt;
	background:navy;
	font-size:11.0pt;
	font-family:"Tahoma",sans-serif;}
p.MsoPlainText, li.MsoPlainText, div.MsoPlainText
	{mso-style-link:"Plain Text Char";
	margin:0in;
	line-height:normal;
	font-size:10.5pt;
	font-family:Consolas;}
p.MsoAutoSig, li.MsoAutoSig, div.MsoAutoSig
	{mso-style-link:"E-mail Signature Char";
	margin:0in;
	line-height:normal;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p
	{margin:0in;
	line-height:13.0pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
address
	{mso-style-link:"HTML Address Char";
	margin:0in;
	margin-bottom:.0001pt;
	line-height:normal;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-style:italic;}
pre
	{mso-style-link:"HTML Preformatted Char";
	margin:0in;
	margin-bottom:.0001pt;
	line-height:normal;
	font-size:10.0pt;
	font-family:Consolas;}
p.MsoCommentSubject, li.MsoCommentSubject, div.MsoCommentSubject
	{mso-style-link:"Comment Subject Char";
	margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.MsoAcetate, li.MsoAcetate, div.MsoAcetate
	{mso-style-link:"Balloon Text Char";
	margin:0in;
	line-height:13.0pt;
	font-size:8.0pt;
	font-family:"Tahoma",sans-serif;}
p.MsoNoSpacing, li.MsoNoSpacing, div.MsoNoSpacing
	{margin:0in;
	line-height:normal;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoRMPane, li.MsoRMPane, div.MsoRMPane
	{margin:0in;
	line-height:normal;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListParagraph, li.MsoListParagraph, div.MsoListParagraph
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListParagraphCxSpFirst, li.MsoListParagraphCxSpFirst, div.MsoListParagraphCxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListParagraphCxSpMiddle, li.MsoListParagraphCxSpMiddle, div.MsoListParagraphCxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListParagraphCxSpLast, li.MsoListParagraphCxSpLast, div.MsoListParagraphCxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoQuote, li.MsoQuote, div.MsoQuote
	{mso-style-link:"Quote Char";
	margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;
	font-style:italic;}
p.MsoIntenseQuote, li.MsoIntenseQuote, div.MsoIntenseQuote
	{mso-style-link:"Intense Quote Char";
	margin-top:10.0pt;
	margin-right:.65in;
	margin-bottom:14.0pt;
	margin-left:.65in;
	line-height:13.0pt;
	border:none;
	padding:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:#4F81BD;
	font-weight:bold;
	font-style:italic;}
p.MsoBibliography, li.MsoBibliography, div.MsoBibliography
	{margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoTocHeading, li.MsoTocHeading, div.MsoTocHeading
	{margin-top:24.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:14.0pt;
	font-family:"Cambria",serif;
	color:#365F91;
	font-weight:bold;}
p.EMEAEnBodyText, li.EMEAEnBodyText, div.EMEAEnBodyText
	{mso-style-name:"EMEA En Body Text";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	text-align:justify;
	line-height:normal;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.AHeader1, li.AHeader1, div.AHeader1
	{mso-style-name:"AHeader 1";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:14.2pt;
	text-indent:-14.2pt;
	line-height:normal;
	font-size:12.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
p.AHeader2, li.AHeader2, div.AHeader2
	{mso-style-name:"AHeader 2";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:35.45pt;
	text-indent:-21.25pt;
	line-height:normal;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
p.AHeader3, li.AHeader3, div.AHeader3
	{mso-style-name:"AHeader 3";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:63.8pt;
	text-indent:-28.35pt;
	line-height:normal;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
p.AHeader2abc, li.AHeader2abc, div.AHeader2abc
	{mso-style-name:"AHeader 2 abc";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:63.8pt;
	text-align:justify;
	text-indent:-28.35pt;
	line-height:normal;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;}
p.AHeader3abc, li.AHeader3abc, div.AHeader3abc
	{mso-style-name:"AHeader 3 abc";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:85.05pt;
	text-align:justify;
	text-indent:-21.25pt;
	line-height:normal;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;}
p.Default, li.Default, div.Default
	{mso-style-name:Default;
	margin:0in;
	line-height:normal;
	text-autospace:none;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.BodytextAgency, li.BodytextAgency, div.BodytextAgency
	{mso-style-name:"Body text \(Agency\)";
	mso-style-link:"Body text \(Agency\) Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:7.0pt;
	margin-left:0in;
	line-height:14.0pt;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
span.BodytextAgencyChar
	{mso-style-name:"Body text \(Agency\) Char";
	mso-style-link:"Body text \(Agency\)";
	font-family:"Verdana",sans-serif;}
span.FootnoteTextChar
	{mso-style-name:"Footnote Text Char";
	mso-style-link:"Footnote Text";}
span.HeaderChar
	{mso-style-name:"Header Char";
	mso-style-link:Header;
	font-family:"Helvetica",sans-serif;}
span.BalloonTextChar
	{mso-style-name:"Balloon Text Char";
	mso-style-link:"Balloon Text";
	font-family:"Tahoma",sans-serif;}
span.Heading1Char
	{mso-style-name:"Heading 1 Char";
	mso-style-link:"Heading 1";
	text-transform:uppercase;
	font-weight:bold;}
span.Heading2Char
	{mso-style-name:"Heading 2 Char";
	mso-style-link:"Heading 2";
	font-family:"Helvetica",sans-serif;
	font-weight:bold;
	font-style:italic;}
span.Heading3Char
	{mso-style-name:"Heading 3 Char";
	mso-style-link:"Heading 3";
	font-weight:bold;}
span.Heading4Char
	{mso-style-name:"Heading 4 Char";
	mso-style-link:"Heading 4";
	font-weight:bold;}
span.Heading5Char
	{mso-style-name:"Heading 5 Char";
	mso-style-link:"Heading 5";}
span.Heading6Char
	{mso-style-name:"Heading 6 Char";
	mso-style-link:"Heading 6";
	font-style:italic;}
span.Heading7Char
	{mso-style-name:"Heading 7 Char";
	mso-style-link:"Heading 7";
	font-style:italic;}
span.Heading8Char
	{mso-style-name:"Heading 8 Char";
	mso-style-link:"Heading 8";
	font-weight:bold;
	font-style:italic;}
span.Heading9Char
	{mso-style-name:"Heading 9 Char";
	mso-style-link:"Heading 9";
	font-weight:bold;
	font-style:italic;}
span.FooterChar
	{mso-style-name:"Footer Char";
	mso-style-link:Footer;
	font-family:"Helvetica",sans-serif;}
span.BodyTextIndentChar
	{mso-style-name:"Body Text Indent Char";
	mso-style-link:"Body Text Indent";}
span.BodyText3Char
	{mso-style-name:"Body Text 3 Char";
	mso-style-link:"Body Text 3";
	color:blue;}
span.BodyTextIndent2Char
	{mso-style-name:"Body Text Indent 2 Char";
	mso-style-link:"Body Text Indent 2";
	color:blue;
	font-weight:bold;}
span.BodyTextChar
	{mso-style-name:"Body Text Char";
	mso-style-link:"Body Text";
	color:green;
	font-style:italic;}
span.BodyText2Char
	{mso-style-name:"Body Text 2 Char";
	mso-style-link:"Body Text 2";
	color:blue;
	font-weight:bold;
	text-decoration:underline;}
span.CommentTextChar
	{mso-style-name:"Comment Text Char";
	mso-style-link:"Comment Text";}
span.DocumentMapChar
	{mso-style-name:"Document Map Char";
	mso-style-link:"Document Map";
	font-family:"Tahoma",sans-serif;
	background:navy;}
span.BodyTextIndent3Char
	{mso-style-name:"Body Text Indent 3 Char";
	mso-style-link:"Body Text Indent 3";}
span.CommentSubjectChar
	{mso-style-name:"Comment Subject Char";
	mso-style-link:"Comment Subject";
	font-weight:bold;}
p.NormalAgency, li.NormalAgency, div.NormalAgency
	{mso-style-name:"Normal \(Agency\)";
	mso-style-link:"Normal \(Agency\) Char";
	margin:0in;
	line-height:normal;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
p.TabletextrowsAgency, li.TabletextrowsAgency, div.TabletextrowsAgency
	{mso-style-name:"Table text rows \(Agency\)";
	margin:0in;
	line-height:14.0pt;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
span.NormalAgencyChar
	{mso-style-name:"Normal \(Agency\) Char";
	mso-style-link:"Normal \(Agency\)";
	font-family:"Verdana",sans-serif;}
p.NormalParagraphStyle, li.NormalParagraphStyle, div.NormalParagraphStyle
	{mso-style-name:NormalParagraphStyle;
	margin:0in;
	line-height:120%;
	text-autospace:none;
	font-size:12.0pt;
	font-family:Times-Roman;
	color:black;}
p.Musterberschrift112, li.Musterberschrift112, div.Musterberschrift112
	{mso-style-name:Muster_Überschrift1_12;
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:12.0pt;
	margin-left:28.35pt;
	line-height:normal;
	text-autospace:none;
	font-size:12.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
span.EndnoteTextChar
	{mso-style-name:"Endnote Text Char";
	mso-style-link:"Endnote Text";}
p.TitleA, li.TitleA, div.TitleA
	{mso-style-name:"Title A";
	margin:0in;
	text-align:center;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.TitleB, li.TitleB, div.TitleB
	{mso-style-name:"Title B";
	margin-top:14.0pt;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:28.1pt;
	text-indent:-28.1pt;
	line-height:13.0pt;
	page-break-after:avoid;
	text-autospace:none;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;
	font-weight:bold;}
span.SalutationChar
	{mso-style-name:"Salutation Char";
	mso-style-link:Salutation;}
span.DateChar
	{mso-style-name:"Date Char";
	mso-style-link:Date;}
span.E-mailSignatureChar
	{mso-style-name:"E-mail Signature Char";
	mso-style-link:"E-mail Signature";}
span.NoteHeadingChar
	{mso-style-name:"Note Heading Char";
	mso-style-link:"Note Heading";}
span.ClosingChar
	{mso-style-name:"Closing Char";
	mso-style-link:Closing;}
span.HTMLAddressChar
	{mso-style-name:"HTML Address Char";
	mso-style-link:"HTML Address";
	font-style:italic;}
span.HTMLPreformattedChar
	{mso-style-name:"HTML Preformatted Char";
	mso-style-link:"HTML Preformatted";
	font-family:Consolas;}
span.IntenseQuoteChar
	{mso-style-name:"Intense Quote Char";
	mso-style-link:"Intense Quote";
	color:#4F81BD;
	font-weight:bold;
	font-style:italic;}
span.MacroTextChar
	{mso-style-name:"Macro Text Char";
	mso-style-link:"Macro Text";
	font-family:Consolas;}
span.MessageHeaderChar
	{mso-style-name:"Message Header Char";
	mso-style-link:"Message Header";
	font-family:"Cambria",serif;
	background:#CCCCCC;}
span.PlainTextChar
	{mso-style-name:"Plain Text Char";
	mso-style-link:"Plain Text";
	font-family:Consolas;}
span.BodyTextFirstIndentChar
	{mso-style-name:"Body Text First Indent Char";
	mso-style-link:"Body Text First Indent";
	color:green;
	font-style:normal;}
span.BodyTextFirstIndent2Char
	{mso-style-name:"Body Text First Indent 2 Char";
	mso-style-link:"Body Text First Indent 2";}
span.TitleChar
	{mso-style-name:"Title Char";
	mso-style-link:Title;
	font-family:"Cambria",serif;
	color:#17365D;
	letter-spacing:.25pt;}
span.SignatureChar
	{mso-style-name:"Signature Char";
	mso-style-link:Signature;}
span.SubtitleChar
	{mso-style-name:"Subtitle Char";
	mso-style-link:Subtitle;
	font-family:"Cambria",serif;
	color:#4F81BD;
	letter-spacing:.75pt;
	font-style:italic;}
span.QuoteChar
	{mso-style-name:"Quote Char";
	mso-style-link:Quote;
	color:black;
	font-style:italic;}
p.Normal11pt, li.Normal11pt, div.Normal11pt
	{mso-style-name:"Normal + 11 pt\,Bold";
	margin:0in;
	line-height:normal;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.mdTblEntry, li.mdTblEntry, div.mdTblEntry
	{mso-style-name:"md_Tbl Entry";
	margin:0in;
	line-height:12.95pt;
	page-break-after:avoid;
	punctuation-wrap:simple;
	text-autospace:none;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.xnormal11pt, li.xnormal11pt, div.xnormal11pt
	{mso-style-name:x_normal11pt;
	margin:0in;
	line-height:normal;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
.MsoChpDefault
	{font-size:10.0pt;}
 /* Page Definitions */
 @page WordSection1
	{size:595.35pt 842.0pt;
	margin:56.7pt 70.85pt 56.7pt 70.9pt;}
div.WordSection1
	{page:WordSection1;}
 /* List Definitions */
 ol
	{margin-bottom:0in;}
ul
	{margin-bottom:0in;}
-->
</style>

</head>

<body lang=EN-US link=blue vlink=purple style='word-wrap:break-word'>

<div class=WordSection1>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>ANNEX
I</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=TitleA><span lang=EN-GB>SUMMARY OF PRODUCT CHARACTERISTICS</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:green'><br clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>1.       </span></b><b><span
lang=EN-GB>NAME OF THE MEDICINAL PRODUCT</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-1.0pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>Armisarte 25&nbsp;mg/ml concentrate for solution for
infusion</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>2.       QUALITATIVE AND QUANTITATIVE COMPOSITION</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Each ml of
concentrate contains 25&nbsp;mg pemetrexed (as pemetrexed diacid).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Each vial of 4&nbsp;ml
concentrate contains 100&nbsp;mg pemetrexed (as pemetrexed diacid).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Each vial of 20&nbsp;ml
concentrate contains 500&nbsp;mg pemetrexed (as pemetrexed diacid).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Each vial of
34&nbsp;ml concentrate contains 850&nbsp;mg pemetrexed (as pemetrexed diacid).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Each vial of 40&nbsp;ml
concentrate contains 1000&nbsp;mg pemetrexed (as pemetrexed diacid).</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-1.0pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>For the full list of excipients see section&nbsp;6.1.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><b><span lang=EN-GB>3.       PHARMACEUTICAL <span
style='text-transform:uppercase'>form</span></span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-1.0pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>Concentrate for solution for infusion (sterile
concentrate).</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The concentrate
is clear, colourless to slightly yellowish or yellow-greenish solution.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The pH is
between&nbsp;7.0 and&nbsp;8.0.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB style='text-transform:uppercase'>4.       Clinical
particulars</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>4.1     Therapeutic indications</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;text-autospace:
none'><u><span lang=EN-GB>Malignant pleural mesothelioma</span></u></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>Pemetrexed in combination with cisplatin is indicated
for the treatment of chemotherapy naïve patients with unresectable malignant
pleural mesothelioma.</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;text-autospace:
none'><u><span lang=EN-GB>Non-small cell lung cancer</span></u></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>Pemetrexed in combination with cisplatin is indicated for
the first line treatment of patients with locally advanced or metastatic
non-small cell lung cancer other than predominantly squamous cell histology
(see section&nbsp;5.1).</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>Pemetrexed is indicated as monotherapy for the
maintenance treatment of locally advanced or metastatic non-small cell lung
cancer other than predominantly squamous cell histology in patients whose
disease has not progressed immediately following platinum-based chemotherapy
(see section&nbsp;5.1).</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>Pemetrexed is indicated as monotherapy for the second
line treatment of patients with locally advanced or metastatic non-small cell
lung cancer other than predominantly squamous cell histology (see section&nbsp;5.1).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>4.2     Posology and method of administration</span></b></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Posology</span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>Pemetrexed must only be administered under the
supervision of a physician qualified in the use of anti-cancer chemotherapy.</span></p>

<p class=MsoNormal style='margin-right:32.95pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><i><span lang=EN-GB>Pemetrexed in combination with cisplatin</span></i></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;page-break-after:
avoid;text-autospace:none'><span lang=EN-GB>The recommended dose of pemetrexed
is 500&nbsp;mg/m<sup>2</sup> of body surface area (BSA) administered as an
intravenous infusion over 10&nbsp;minutes on the first day of each 21-day
cycle. The recommended dose of cisplatin is 75&nbsp;mg/m<sup>2</sup> BSA
infused over two hours approximately 30&nbsp;minutes after completion of the
pemetrexed infusion on the first day of each 21-day cycle. <u>Patients must
receive adequate anti-emetic treatment and appropriate hydration prior to
and/or after receiving cisplatin</u> (see also cisplatin Summary of Product
Characteristics for specific dosing advice).</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-1.0pt;line-height:normal;text-autospace:
none'><i><span lang=EN-GB>Pemetrexed as single agent</span></i></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>In patients treated for non-small cell lung cancer after
prior chemotherapy, the recommended dose of pemetrexed is 500&nbsp;mg/m<sup>2</sup>
BSA administered as an intravenous infusion over 10&nbsp;minutes on the first
day of each 21-day cycle.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-1.0pt;line-height:normal;text-autospace:
none'><i><span lang=EN-GB>Pre-medication regimen</span></i></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>To reduce the incidence and severity of skin reactions,
a corticosteroid should be given the day prior to, on the day of, and the day
after pemetrexed administration. The corticosteroid should be equivalent to
4&nbsp;mg of dexamethasone administered orally twice a day (see section&nbsp;4.4).</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>To reduce toxicity, patients treated with pemetrexed
must also receive vitamin supplementation (see&nbsp;section&nbsp;4.4). Patients
must take oral folic acid or a multivitamin containing folic acid (350&nbsp;to
1000&nbsp;micrograms) on a daily basis. At least five doses of folic acid must
be taken during the seven days preceding the first dose of pemetrexed, and
dosing must continue during the full course of therapy and for 21&nbsp;days
after the last dose of pemetrexed. Patients must also receive an intramuscular
injection of vitamin B<sub>12</sub> (1000&nbsp;micrograms) in the week
preceding the first dose of pemetrexed and once every three cycles thereafter.
Subsequent vitamin B<sub>12</sub> injections may be given on the same day as
pemetrexed.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-1.0pt;line-height:normal;text-autospace:
none'><i><span lang=EN-GB>Monitoring</span></i></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>Patients receiving pemetrexed should be monitored before
each dose with a complete blood count, including a differential white cell
count (WCC) and platelet count. Prior to each chemotherapy administration blood
chemistry tests should be collected to evaluate renal and hepatic function.
Before the start of any cycle of chemotherapy, patients are required to have
the following: absolute neutrophil count (ANC) should be
&#8805;&nbsp;1500&nbsp;cells/mm<sup>3</sup> and platelets should be
&#8805;&nbsp;100,000 cells/mm<sup>3</sup>.</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>Creatinine clearance should be &#8805; 45&nbsp;ml/min.</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>The total bilirubin should be &#8804; 1.5&nbsp;times
upper limit of normal. Alkaline phosphatase (AP), aspartate aminotransferase
(AST or SGOT) and alanine aminotransferase (ALT or SGPT) should be
&#8804;&nbsp;3&nbsp;times upper limit of normal. Alkaline phosphatase, AST and
ALT &#8804;&nbsp;5&nbsp;times upper limit of normal is acceptable if liver has
tumour involvement.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-1.0pt;line-height:normal;text-autospace:
none'><i><span lang=EN-GB>Dose adjustments</span></i></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>Dose adjustments at the start of a subsequent cycle
should be based on nadir haematologic counts or maximum non-haematologic
toxicity from the preceding cycle of therapy. Treatment may be delayed to allow
sufficient time for recovery. Upon recovery patients should be retreated using
the guidelines in Tables&nbsp;1,&nbsp;2 and&nbsp;3, which are applicable for
pemetrexed used as a single agent or in combination with cisplatin.</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0
 style='margin-left:.25pt;border-collapse:collapse'>
 <tr style='height:30.0pt'>
  <td width=577 colspan=2 valign=top style='width:432.85pt;border:solid black 1.0pt;
  padding:0in 0in 0in 0in;height:30.0pt'><span lang=EN-GB style='font-size:
  11.0pt;font-family:"Times New Roman",serif'><br clear=all style='page-break-before:
  always'>
  </span>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><b><span lang=EN-GB>Table&nbsp;1 - Dose modification
  table for pemetrexed (as single agent or in combination) and cisplatin 
  Haematologic toxicities</span></b></p>
  </td>
 </tr>
 <tr style='height:26.65pt'>
  <td width=296 valign=top style='width:222.25pt;border:solid black 1.0pt;
  border-top:none;padding:0in 0in 0in 0in;height:26.65pt'>
  <p class=MsoNormal style='margin-left:5.0pt;line-height:normal;text-autospace:
  none'><span lang=EN-GB>Nadir ANC &lt; 500/mm<sup>3</sup> and nadir platelets</span></p>
  <p class=MsoNormal style='margin-left:5.0pt;line-height:normal;text-autospace:
  none'><span lang=EN-GB>&#8805; 50,000 /mm<sup>3</sup></span></p>
  </td>
  <td width=281 valign=top style='width:210.6pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in;height:26.65pt'>
  <p class=MsoNormal style='margin-left:5.1pt;line-height:normal;text-autospace:
  none'><span lang=EN-GB>75%&nbsp;of previous dose (both pemetrexed and
  cisplatin)</span></p>
  </td>
 </tr>
 <tr style='height:25.8pt'>
  <td width=296 valign=top style='width:222.25pt;border:solid black 1.0pt;
  border-top:none;padding:0in 0in 0in 0in;height:25.8pt'>
  <p class=MsoNormal style='margin-left:5.0pt;line-height:normal;text-autospace:
  none'><span lang=EN-GB>Nadir platelets  &lt;50,000 /mm <sup>3</sup>
  regardless of nadir ANC</span></p>
  <p class=MsoNormal style='margin-left:5.0pt;line-height:normal;text-autospace:
  none'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:5.0pt;line-height:normal;text-autospace:
  none'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=281 valign=top style='width:210.6pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in;height:25.8pt'>
  <p class=MsoNormal style='margin-left:5.1pt;line-height:normal;text-autospace:
  none'><span lang=EN-GB>75%&nbsp;of previous dose (both pemetrexed and
  cisplatin)</span></p>
  </td>
 </tr>
 <tr style='height:32.45pt'>
  <td width=296 valign=top style='width:222.25pt;border:solid black 1.0pt;
  border-top:none;padding:0in 0in 0in 0in;height:32.45pt'>
  <p class=MsoNormal style='margin-left:5.0pt;line-height:normal;text-autospace:
  none'><span lang=EN-GB>Nadir platelets &lt;50,000/mm <sup>3</sup> with
  bleeding<sup>a</sup>, regardless of nadir ANC</span></p>
  </td>
  <td width=281 valign=top style='width:210.6pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in;height:32.45pt'>
  <p class=MsoNormal style='margin-left:5.1pt;line-height:normal;text-autospace:
  none'><span lang=EN-GB>50%&nbsp;of previous dose (both pemetrexed and
  cisplatin)</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
0in;margin-left:18.9pt;margin-bottom:.0001pt;line-height:normal;text-autospace:
none'><sup><span lang=EN-GB style='font-size:10.0pt'>a</span></sup><span
lang=EN-GB style='font-size:10.0pt'> These criteria meet the National Cancer
Institute Common Toxicity Criteria (CTC v2.0; NCI 1998) definition of
&#8805;CTC Grade 2 bleeding.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
0in;margin-left:18.9pt;margin-bottom:.0001pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>If patients develop non-haematologic toxicities &#8805;
Grade&nbsp;3 (excluding neurotoxicity), pemetrexed should be withheld until resolution
to less than or equal to the patients pre-therapy value. Treatment should be
resumed according to the guidelines in Table&nbsp;2.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0
 style='margin-left:.25pt;border-collapse:collapse'>
 <tr style='height:34.25pt'>
  <td width=576 colspan=3 valign=top style='width:432.35pt;border:solid black 1.0pt;
  padding:0in 0in 0in 0in;height:34.25pt'>
  <p class=MsoNormal align=center style='margin-right:15.35pt;text-align:center;
  text-indent:.95pt;line-height:normal;text-autospace:none'><b><span
  lang=EN-GB>Table&nbsp;2 - Dose modification table for pemetrexed (as single
  agent or in combination) and cisplatin Non-haematologic toxicities<sup>a,b</sup></span></b></p>
  <p class=MsoNormal style='margin-top:0in;margin-right:15.35pt;margin-bottom:
  0in;margin-left:133.75pt;margin-bottom:.0001pt;text-indent:-115.55pt;
  line-height:normal;text-autospace:none'><b><sup><span lang=EN-GB>&nbsp;</span></sup></b></p>
  <p class=MsoNormal style='margin-top:0in;margin-right:15.35pt;margin-bottom:
  0in;margin-left:133.75pt;margin-bottom:.0001pt;text-indent:-115.55pt;
  line-height:normal;text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:28.05pt'>
  <td width=230 valign=top style='width:172.7pt;border:solid black 1.0pt;
  border-top:none;padding:0in 0in 0in 0in;height:28.05pt'>
  <p class=MsoNormal style='margin-right:15.35pt;line-height:normal;text-autospace:
  none'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=176 valign=top style='width:132.1pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in;height:28.05pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:15.35pt;
  margin-bottom:0in;margin-left:4.5pt;margin-bottom:.0001pt;text-align:center;
  line-height:normal;text-autospace:none'><b><span lang=EN-GB>Dose of
  pemetrexed (mg/m<sup>2</sup>)</span></b></p>
  </td>
  <td width=170 valign=top style='width:127.55pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in;height:28.05pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:15.35pt;
  margin-bottom:0in;margin-left:7.05pt;margin-bottom:.0001pt;text-align:center;
  line-height:normal;text-autospace:none'><b><span lang=EN-GB>Dose for
  cisplatin (mg/m<sup>2</sup>)</span></b></p>
  </td>
 </tr>
 <tr style='height:28.75pt'>
  <td width=230 valign=top style='width:172.7pt;border:solid black 1.0pt;
  border-top:none;padding:0in 0in 0in 0in;height:28.75pt'>
  <p class=MsoNormal style='margin-top:0in;margin-right:15.35pt;margin-bottom:
  0in;margin-left:5.0pt;margin-bottom:.0001pt;line-height:normal;text-autospace:
  none'><span lang=EN-GB>Any Grade 3&nbsp;or 4&nbsp;toxicities except mucositis</span></p>
  </td>
  <td width=176 valign=top style='width:132.1pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in;height:28.75pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:15.35pt;
  margin-bottom:0in;margin-left:4.5pt;margin-bottom:.0001pt;text-align:center;
  line-height:normal;text-autospace:none'><span lang=EN-GB>75%&nbsp;of previous
  dose</span></p>
  </td>
  <td width=170 valign=top style='width:127.55pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in;height:28.75pt'>
  <p class=MsoNormal align=center style='margin-right:15.35pt;text-align:center;
  line-height:normal;text-autospace:none'><span lang=EN-GB>75%&nbsp;of previous
  dose</span></p>
  </td>
 </tr>
 <tr style='height:42.7pt'>
  <td width=230 valign=top style='width:172.7pt;border:solid black 1.0pt;
  border-top:none;padding:0in 0in 0in 0in;height:42.7pt'>
  <p class=MsoNormal style='margin-top:0in;margin-right:15.35pt;margin-bottom:
  0in;margin-left:5.0pt;margin-bottom:.0001pt;line-height:normal;text-autospace:
  none'><span lang=EN-GB>Any diarrhoea requiring hospitalisation (irrespective
  of grade) or grade 3&nbsp;or&nbsp;4&nbsp;diarrhoea.</span></p>
  </td>
  <td width=176 valign=top style='width:132.1pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in;height:42.7pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:15.35pt;
  margin-bottom:0in;margin-left:4.5pt;margin-bottom:.0001pt;text-align:center;
  line-height:normal;text-autospace:none'><span lang=EN-GB>75%&nbsp;of previous
  dose</span></p>
  </td>
  <td width=170 valign=top style='width:127.55pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in;height:42.7pt'>
  <p class=MsoNormal align=center style='margin-right:15.35pt;text-align:center;
  line-height:normal;text-autospace:none'><span lang=EN-GB>75%&nbsp;of previous
  dose</span></p>
  </td>
 </tr>
 <tr style='height:25.3pt'>
  <td width=230 valign=top style='width:172.7pt;border:solid black 1.0pt;
  border-top:none;padding:0in 0in 0in 0in;height:25.3pt'>
  <p class=MsoNormal style='margin-top:0in;margin-right:15.35pt;margin-bottom:
  0in;margin-left:5.0pt;margin-bottom:.0001pt;line-height:normal;text-autospace:
  none'><span lang=EN-GB>Grade 3&nbsp;or&nbsp;4&nbsp;mucositis</span></p>
  </td>
  <td width=176 valign=top style='width:132.1pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in;height:25.3pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:15.35pt;
  margin-bottom:0in;margin-left:4.5pt;margin-bottom:.0001pt;text-align:center;
  line-height:normal;text-autospace:none'><span lang=EN-GB>50%&nbsp;of previous
  dose</span></p>
  </td>
  <td width=170 valign=top style='width:127.55pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in;height:25.3pt'>
  <p class=MsoNormal align=center style='margin-right:15.35pt;text-align:center;
  line-height:normal;text-autospace:none'><span lang=EN-GB>100%&nbsp;of
  previous dose</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-top:0in;margin-right:44.85pt;margin-bottom:
0in;margin-left:18.9pt;margin-bottom:.0001pt;line-height:normal;text-autospace:
none'><sup><span lang=EN-GB style='font-size:10.0pt'>a</span></sup><span
lang=EN-GB style='font-size:10.0pt'> National Cancer Institute Common Toxicity
Criteria (CTC v2.0; NCI 1998)</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:44.85pt;margin-bottom:
0in;margin-left:18.9pt;margin-bottom:.0001pt;line-height:normal;text-autospace:
none'><sup><span lang=EN-GB style='font-size:10.0pt'>b</span></sup><span
lang=EN-GB style='font-size:10.0pt'> Excluding neurotoxicity</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>In the event of neurotoxicity, the recommended dose
adjustment for pemetrexed and cisplatin is documented in Table&nbsp;3. Patients
should discontinue therapy if Grade 3&nbsp;or&nbsp;4&nbsp;neurotoxicity is
observed.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0
 style='margin-left:.25pt;border-collapse:collapse'>
 <tr style='height:28.75pt'>
  <td width=580 colspan=3 valign=top style='width:434.9pt;border:solid black 1.0pt;
  padding:0in 0in 0in 0in;height:28.75pt'>
  <p class=MsoNormal align=center style='margin-right:11.95pt;text-align:center;
  line-height:normal;text-autospace:none'><b><span lang=EN-GB>Table&nbsp;3 -
  Dose modification table for pemetrexed (as single agent or in combination)
  and cisplatin  Neurotoxicity</span></b></p>
  </td>
 </tr>
 <tr style='height:25.3pt'>
  <td width=174 valign=top style='width:130.2pt;border:solid black 1.0pt;
  border-top:none;padding:0in 0in 0in 0in;height:25.3pt'>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.0pt;margin-bottom:.0001pt;line-height:normal;text-autospace:
  none'><b><span lang=EN-GB>CTC<sup>a</sup> Grade</span></b></p>
  </td>
  <td width=208 valign=top style='width:155.9pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in;height:25.3pt'>
  <p class=MsoNormal style='margin-right:-1.0pt;line-height:normal;text-autospace:
  none'><b><span lang=EN-GB>Dose of pemetrexed (mg/m<sup>2</sup>)</span></b></p>
  </td>
  <td width=198 valign=top style='width:148.8pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in;height:25.3pt'>
  <p class=MsoNormal style='margin-right:-1.0pt;line-height:normal;text-autospace:
  none'><b><span lang=EN-GB>Dose for cisplatin (mg/m<sup>2</sup>)</span></b></p>
  </td>
 </tr>
 <tr style='height:.35in'>
  <td width=174 valign=top style='width:130.2pt;border:solid black 1.0pt;
  border-top:none;padding:0in 0in 0in 0in;height:.35in'>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.0pt;margin-bottom:.0001pt;line-height:normal;text-autospace:
  none'><span lang=EN-GB>0  1</span></p>
  </td>
  <td width=208 valign=top style='width:155.9pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in;height:.35in'>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:29.35pt;margin-bottom:.0001pt;line-height:normal;text-autospace:
  none'><span lang=EN-GB>100%&nbsp;of previous dose</span></p>
  </td>
  <td width=198 valign=top style='width:148.8pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in;height:.35in'>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:25.85pt;margin-bottom:.0001pt;line-height:normal;text-autospace:
  none'><span lang=EN-GB>100%&nbsp;of previous dose</span></p>
  </td>
 </tr>
 <tr style='height:25.3pt'>
  <td width=174 valign=top style='width:130.2pt;border:solid black 1.0pt;
  border-top:none;padding:0in 0in 0in 0in;height:25.3pt'>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.0pt;margin-bottom:.0001pt;line-height:normal;text-autospace:
  none'><span lang=EN-GB>2</span></p>
  </td>
  <td width=208 valign=top style='width:155.9pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in;height:25.3pt'>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:25.5pt;margin-bottom:.0001pt;line-height:normal;text-autospace:
  none'><span lang=EN-GB>100%&nbsp;of previous dose</span></p>
  </td>
  <td width=198 valign=top style='width:148.8pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in;height:25.3pt'>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:24.8pt;margin-bottom:.0001pt;line-height:normal;text-autospace:
  none'><span lang=EN-GB>50%&nbsp;of previous dose</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
0in;margin-left:18.9pt;margin-bottom:.0001pt;line-height:normal;text-autospace:
none'><sup><span lang=EN-GB style='font-size:10.0pt'>a</span></sup><span
lang=EN-GB style='font-size:10.0pt'> National Cancer Institute Common Toxicity
Criteria (CTC v2.0; NCI 1998)</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>Treatment with pemetrexed should be discontinued if a
patient experiences any haematologic or non-haematologic Grade 3&nbsp;or&nbsp;4&nbsp;toxicity
after 2&nbsp;dose reductions or immediately if Grade 3&nbsp;or&nbsp;4 neurotoxicity
is observed.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;text-autospace:
none'><i><span lang=EN-GB>Special populations</span></i></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;text-autospace:
none'><i><span lang=EN-GB>Elderly</span></i></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>In clinical studies, there has been no indication that
patients 65&nbsp;years of age or older are at increased risk of adverse reactions
compared to patients younger than 65&nbsp;years old. No dose reductions other
than those recommended for all patients are necessary.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-1.15pt;line-height:normal;text-autospace:
none'><i><span lang=EN-GB>Paediatric population</span></i></p>

<p class=MsoNormal style='margin-right:-1.15pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>There is no relevant use of pemetrexed in the paediatric
population in malignant pleural mesothelioma and non-small cell lung cancer.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;text-autospace:
none'><i><span lang=EN-GB>Patients with renal impairment</span></i><i><span
lang=EN-GB> (standard cockcroft and gault formula or glomerular filtration rate
measured Tc99m-DPTA serum clearance method)</span></i></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>Pemetrexed is primarily eliminated unchanged by renal
excretion. In clinical studies, patients with creatinine clearance of
&#8805;&nbsp;45 ml/min required no dose adjustments other than those
recommended for all patients. There are insufficient data on the use of
pemetrexed in patients with creatinine clearance below 45&nbsp;ml/min;
therefore the use of pemetrexed is not recommended (see section&nbsp;4.4).</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><i><span lang=EN-GB>Patients with hepatic impairment</span></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB>No relationships between AST (SGOT), ALT (SGPT), or
total bilirubin and pemetrexed pharmacokinetics were identified. However
patients with hepatic impairment such as bilirubin &gt;&nbsp;1.5 times the
upper limit of normal and/or aminotransferase &gt;&nbsp;3.0 times the upper
limit of normal (hepatic metastases absent) or &gt;&nbsp;5.0 times the upper
limit of normal (hepatic metastases present) have not been specifically
studied.</span></p>

<p class=MsoNormal style='margin-right:-1.0pt;line-height:normal;text-autospace:
none'><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='margin-right:-1.0pt;line-height:normal;text-autospace:
none'><u><span lang=EN-GB>Method of administration</span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-1.0pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>Armisarte is for intravenous use. It should be
administered as an intravenous infusion over 10&nbsp;minutes on the first day
of each 21-day cycle.</span></p>

<p class=MsoNormal style='margin-right:-1.0pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-1.0pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>For precautions to be taken before handling or
administering pemetrexed andfor instructions on dilution of Armisarte before
administration, see section&nbsp;6.6.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>4.3     Contraindications</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>Hypersensitivity to the active substance or to any of
the excipients listed in section&nbsp;6.1.</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>Breast-feeding (see section&nbsp;4.6)<i>.</i></span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-1.0pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>Concomitant yellow fever vaccine (see section&nbsp;4.5).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>4.4     Special warnings and precautions for use</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>Pemetrexed can suppress bone marrow function as
manifested by neutropenia, thrombocytopenia and anaemia (or pancytopenia) (see
section 4.8). Myelosuppression is usually the dose-limiting toxicity. Patients
should be monitored for myelosuppression during therapy and pemetrexed should
not be given to patients until absolute neutrophil count (ANC) returns to
&#8805;&nbsp;1500 cells/mm<sup>3</sup> and platelet count returns to
&#8805;&nbsp;100,000 cells/mm<sup>3</sup>. Dose reductions for subsequent
cycles are based on nadir ANC, platelet count and maximum non-haematologic
toxicity seen from the previous cycle (see section&nbsp;4.2).</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>Less toxicity and reduction in Grade
3/4&nbsp;haematologic and non-haematologic toxicities such as neutropenia,
febrile neutropenia and infection with Grade 3/4&nbsp;neutropenia were reported
when pre-treatment with folic acid and vitamin B<sub>12</sub> was administered.
Therefore, all patients treated with pemetrexed must be instructed to take
folic acid and vitamin B<sub>12</sub> as a prophylactic measure to reduce treatment-related
toxicity (see section&nbsp;4.2).</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>Skin reactions have been reported in patients not
pre-treated with a corticosteroid. Pre-treatment with dexamethasone (or
equivalent) can reduce the incidence and severity of skin reactions (see
section&nbsp;4.2).</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>An insufficient number of patients has been studied with
creatinine clearance of below 45&nbsp;ml/min. Therefore, the use of pemetrexed
in patients with creatinine clearance of &lt; 45&nbsp;ml/min is not recommended
(see section&nbsp;4.2).</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>Patients with mild to moderate renal insufficiency
(creatinine clearance from 45&nbsp;to&nbsp;79&nbsp;ml/min) should avoid taking
non-steroidal anti-inflammatory medicinal products (NSAIDs) such as ibuprofen,
and acetylsalicylic acid (&gt;&nbsp;1.3&nbsp;g&nbsp;daily) for 2&nbsp;days before,
on the day of, and 2&nbsp;days following pemetrexed administration (see
section&nbsp;4.5).</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>In patients with mild to moderate renal insufficiency
eligible for pemetrexed therapy NSAIDs with long elimination half-lives should
be interrupted for at least 5&nbsp;days prior to, on the day of, and at least
2&nbsp;days following pemetrexed administration (see section&nbsp;4.5).</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>Serious renal events, including acute renal failure,
have been reported with pemetrexed alone or in association with other
chemotherapeutic agents. Many of the patients in whom these occurred had
underlying risk factors for the development of renal events including
dehydration or pre-existing hypertension or diabetes. Nephrogenic diabetes insipidus
and renal tubular necrosis were also reported in post marketing setting with
pemetrexed alone or with other chemotherapeutic agents. Most of these events
resolved after pemetrexed withdrawal. Patients should be regularly monitored
for acute tubular necrosis, decreased renal function and signs and symptoms of
nephrogenic diabetes insipidus (e.g. hypernatraemia).</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>The effect of third space fluid, such as pleural
effusion or ascites, on pemetrexed is not fully defined. A phase 2&nbsp;study
of pemetrexed in 31&nbsp;solid tumour patients with stable third space fluid
demonstrated no difference in pemetrexed dose normalized plasma concentrations
or clearance compared to patients without third space fluid collections. Thus,
drainage of third space fluid collection prior to pemetrexed treatment should
be considered, but may not be necessary.</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>Due to the gastrointestinal toxicity of pemetrexed given
in combination with cisplatin, severe dehydration has been observed. Therefore,
patients should receive adequate antiemetic treatment and appropriate hydration
prior to and/or after receiving treatment.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>Serious cardiovascular events, including myocardial
infarction and cerebrovascular events have been uncommonly reported during
clinical studies with pemetrexed, usually when given in combination with
another cytotoxic agent. Most of the patients in whom these events have been
observed had pre-existing cardiovascular risk factors (see section&nbsp;4.8).</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:4.85pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>Immunodepressed status is common in cancer patients. As
a result, concomitant use of live attenuated vaccines is not recommended (see
section&nbsp;4.3&nbsp;and&nbsp;4.5).</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>Pemetrexed can have genetically damaging effects.
Sexually mature males are advised not to father a child during the treatment
and up to 6&nbsp;months thereafter. Contraceptive measures or abstinence are
recommended. Owing to the possibility of pemetrexed treatment causing
irreversible infertility, men are advised to seek counselling on sperm storage
before starting treatment.</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>Women of childbearing potential must use effective
contraception during treatment with pemetrexed (see section&nbsp;4.6).</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>Cases of radiation pneumonitis have been reported in
patients treated with radiation either prior, during or subsequent to their
pemetrexed therapy. Particular attention should be paid to these patients and
caution exercised with use of other radiosensitising agents.</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>Cases of radiation recall have been reported in patients
who received radiotherapy weeks or years previously.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>4.5     Interaction with other medicinal products
and other forms of interaction</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>Pemetrexed is mainly eliminated unchanged renally by
tubular secretion and to a lesser extent by glomerular filtration. Concomitant
administration of nephrotoxic active substances (e.g. aminoglycoside, loop
diuretics, platinum compounds, cyclosporin) could potentially result in delayed
clearance of pemetrexed. This combination should be used with caution. If
necessary, creatinine clearance should be closely monitored.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>Concomitant administration of substances that are also
tubularly secreted (e.g. probenecid, penicillin) could potentially result in
delayed clearance of pemetrexed. Caution should be made when these substances are
combined with pemetrexed. If necessary, creatinine clearance should be closely
monitored.</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>In patients with normal renal function (creatinine
clearance <u>&gt;&nbsp;</u>80 ml/min), high doses of non-steroidal
anti-inflammatory medicinal products (NSAIDs, such as ibuprofen
&gt;&nbsp;1600&nbsp;mg/day) and acetylsalicylic acid at higher dose (<u>&gt;&nbsp;</u>1.3&nbsp;g
daily) may decrease pemetrexed elimination and, consequently, increase the
occurrence of pemetrexed adverse reactions. Therefore, caution should be made
when administering higher doses of NSAIDs or acetylsalicylic acid, concurrently
with pemetrexed to patients with normal function (creatinine clearance <u>&gt;&nbsp;</u>80&nbsp;ml/min).</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>In patients with mild to moderate renal insufficiency
(creatinine clearance from 45&nbsp;to&nbsp;79&nbsp;ml/min), the concomitant
administration of pemetrexed with NSAIDs (e.g. ibuprofen) or acetylsalicylic
acid at higher dose should be avoided for 2&nbsp;days before, on the day of,
and 2&nbsp;days following pemetrexed administration (see section&nbsp;4.4).</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>In the absence of data regarding potential interaction
with NSAIDs having longer half-lives such as piroxicam or rofecoxib, the
concomitant administration with pemetrexed in patients with mild to moderate
renal insufficiency should be interrupted for at least 5&nbsp;days prior to, on
the day of, and at least 2&nbsp;days following pemetrexed administration (see section&nbsp;4.4).
If concomitant administration of NSAIDs is necessary, patients should be
monitored closely for toxicity, especially myelosuppression and
gastrointestinal toxicity.</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>Pemetrexed undergoes limited hepatic metabolism. Results
from <i>in vitro </i>studies with human liver microsomes indicated that
pemetrexed would not be predicted to cause clinically significant inhibition of
the metabolic clearance of active substances metabolised by CYP3A, CYP2D6,
CYP2C9, and CYP1A2.</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;text-autospace:
none'><u><span lang=EN-GB>Interactions common to all cytotoxics</span></u></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>Due to the increased thrombotic risk in patients with
cancer, the use of anticoagulation treatment is frequent. The high
intra-individual variability of the coagulation status during diseases and the
possibility of interaction between oral anticoagulants and anticancer
chemotherapy require increased frequency of INR (International Normalised
Ratio) monitoring, if it is decided to treat the patient with oral
anticoagulants.</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>Concomitant use contraindicated: Yellow fever vaccine:
risk of fatal generalised vaccinale disease (see&nbsp;section&nbsp;4.3).</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>Concomitant use not recommended: Live attenuated
vaccines (except yellow fever, for which concomitant use is contraindicated):
risk of systemic, possibly fatal, disease. The risk is increased in subjects
who are already immunosuppressed by their underlying disease. Use an
inactivated vaccine where it exists (poliomyelitis) (see section&nbsp;4.4).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>4.6     Fertility, pregnancy and lactation</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-1.0pt;line-height:normal;text-autospace:
none'><u><span lang=EN-GB>Women of childbearing potential/Contraception in
males and females</span></u></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>Women of childbearing potential must use effective
contraception during treatment with pemetrexed. Pemetrexed can have genetically
damaging effects. Sexually mature males are advised not to father a child
during the treatment and up to 6&nbsp;months thereafter. Contraceptive measures
or abstinence are recommended.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-1.15pt;line-height:normal;text-autospace:
none'><u><span lang=EN-GB>Pregnancy</span></u></p>

<p class=MsoNormal style='margin-right:-1.0pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>There are no data from the use of pemetrexed in pregnant
women but pemetrexed, like other anti-metabolites, is suspected to cause
serious birth defects when administered during pregnancy. Animal studies have
shown reproductive toxicity (see section&nbsp;5.3). Pemetrexed should not be
used during pregnancy unless clearly necessary, after a careful consideration
of the needs of the mother and the risk for the foetus (see section&nbsp;4.4).</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-1.15pt;line-height:normal;text-autospace:
none'><u><span lang=EN-GB>Breast-feeding</span></u></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>It is unknown whether pemetrexed is excreted in human
milk and adverse reactions on the breast-fed child cannot be excluded.
Breast-feeding must be discontinued during pemetrexed therapy (see
section&nbsp;4.3)<i>.</i></span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-1.0pt;line-height:normal;text-autospace:
none'><u><span lang=EN-GB>Fertility</span></u></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>Owing to the possibility of pemetrexed treatment causing
irreversible infertility, men are advised to seek counselling on sperm storage
before starting treatment.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>4.7     Effects on ability to drive and use
machines</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>Pemetrexed has no or negligible influence on the ability
to drive and use machines. However, it has been reported that pemetrexed may
cause fatigue. Therefore patients should be cautioned against driving or
operating machines if this event occurs.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>4.8     Undesirable effects</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-1.0pt;line-height:normal;text-autospace:
none'><u><span lang=EN-GB>Summary of the safety profile</span></u></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>The most commonly reported undesirable effects related
to pemetrexed, whether used as monotherapy or in combination, are bone marrow
suppression manifested as anaemia, neutropenia, leukopenia, thrombocytopenia;
and gastrointestinal toxicities, manifested as anorexia, nausea, vomiting,
diarrhoea, constipation, pharyngitis, mucositis, and stomatitis. Other
undesirable effects include renal toxicities, increased aminotransferases,
alopecia, fatigue, dehydration, rash, infection/sepsis and neuropathy. Rarely seen
events include Stevens-Johnson syndrome and toxic epidermal necrolysis.</span></p>

<p class=MsoNormal style='margin-right:-1.0pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-1.0pt;line-height:normal;text-autospace:
none'><u><span lang=EN-GB>Tabulated list of adverse reactions</span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoEndnoteText><span style='color:black'>The table 4 lists the adverse
drug events regardless of causality associated with pemetrexed used either as a
monotherapy treatment or in combination with cisplatin from the pivotal
registration studies (</span><span lang=EN-GB>JMCH</span><span
style='color:black'>, </span><span lang=EN-GB>JMEI, JMBD, </span>JMEN and
PARAMOUNT)<span style='color:black'> and from the post marketing period<s>.</s></span></p>

<p class=MsoEndnoteText><s><span style='color:black'><span style='text-decoration:
 none'>&nbsp;</span></span></s></p>

<p class=MsoEndnoteText><span style='color:black'>ADRs are listed by MedDRA
body system organ class. The following convention has been used for
classification of frequency: </span><span lang=EN-GB>very common: &#8805;&nbsp;1/10;
common: &#8805;&nbsp;1/100 to &lt;&nbsp;1/10; uncommon: &#8805;&nbsp;1/1,000 to
&lt;&nbsp;1/100; rare: &#8805;&nbsp;1/10,000 to &lt;&nbsp;1/1,000; very rare:
&lt;&nbsp;1/10,000) <span style='color:black'>and not known (cannot be
estimated from the available data).</span></span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:3.7pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=Normal11pt style='page-break-after:auto'><a name="_Hlk34134743"></a><a
name="_Hlk29538037"><b><span lang=EN-GB>Table 4. Frequencies of all grades adverse
drug events regardless of causality from the pivotal registration studies: JMEI
(pemetrexed vs docetaxel), JMDB (pemetrexed and cisplatin versus gemcitabine and
cisplatin, JMCH (pemetrexed plus cisplatin versus cisplatin), JMEN and
PARAMOUNT (pemetrexed plus best supportive care versus placebo plus best supportive
care) and from post-marketing period.</span></b></a></p>

<p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=684
 style='border-collapse:collapse;border:none'>
 <thead>
  <tr>
   <td width=102 valign=top style='width:76.3pt;border:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=Normal11pt style='page-break-after:auto'><a name="_Hlk30072304"><b>System
   Organ Class </b></a></p>
   <p class=Normal11pt style='page-break-after:auto'><b>(MedDRA)</b></p>
   <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
   </td>
   <td width=104 valign=top style='width:78.0pt;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal><b><span lang=EN-GB>Very common</span></b></p>
   <p class=Normal11pt style='page-break-after:auto'><b><span lang=EN-GB>&nbsp;</span></b></p>
   </td>
   <td width=104 valign=top style='width:77.95pt;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=Normal11pt style='page-break-after:auto'><b><span lang=EN-GB>Common</span></b></p>
   </td>
   <td width=104 valign=top style='width:77.95pt;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=Normal11pt style='page-break-after:auto'><b><span lang=EN-GB>Uncommon</span></b></p>
   </td>
   <td width=104 valign=top style='width:77.95pt;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=Normal11pt style='page-break-after:auto'><b><span lang=EN-GB>Rare</span></b></p>
   </td>
   <td width=85 valign=top style='width:63.8pt;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=Normal11pt style='page-break-after:auto'><b><span lang=EN-GB>Very
   rare</span></b></p>
   </td>
   <td width=81 valign=top style='width:61.0pt;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=Normal11pt style='page-break-after:auto'><b><span lang=EN-GB>Not
   known</span></b></p>
   </td>
  </tr>
 </thead>
 <tr>
  <td width=102 valign=top style='width:76.3pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Infections
  and infestations</span></p>
  </td>
  <td width=104 valign=top style='width:78.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Infection<sup>a</sup></span></p>
  <p class=MsoNormal><span lang=EN-GB>Pharyngitis</span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Sepsis<sup>b</sup></span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Dermohypodermitis</span></p>
  </td>
  <td width=81 valign=top style='width:61.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=102 valign=top style='width:76.3pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Blood and
  lymphatic system disorders</span></p>
  </td>
  <td width=104 valign=top style='width:78.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Neutropenia</span></p>
  <p class=MsoNormal><span lang=EN-GB>Leukopenia</span></p>
  <p class=MsoNormal><span lang=EN-GB>Haemoglobin decreased</span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Febrile
  neutropenia</span></p>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Platelet
  count decreased</span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Pancytopenia</span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Autoimmune
  haemolytic anaemia</span></p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=81 valign=top style='width:61.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=102 valign=top style='width:76.3pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Immune System
  disorders</span></p>
  </td>
  <td width=104 valign=top style='width:78.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Hypersensitivity</span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'>&nbsp;</p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Anaphylactic
  shock</span></p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=81 valign=top style='width:61.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=102 valign=top style='width:76.3pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Metabolism and nutrition disorders</span></p>
  </td>
  <td width=104 valign=top style='width:78.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Dehydration</span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=81 valign=top style='width:61.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=102 valign=top style='width:76.3pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Nervous
  system disorders</span></p>
  </td>
  <td width=104 valign=top style='width:78.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Taste
  disorder</span></p>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Peripheral
  motor neuropathy</span></p>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Peripheral
  sensory neuropathy</span></p>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Dizziness</span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Cerebrovascular
  accident</span></p>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Ischaemic
  stroke</span></p>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Haemorrhage
  intracranial </span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=81 valign=top style='width:61.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=102 valign=top style='width:76.3pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Eye
  disorders</span></p>
  </td>
  <td width=104 valign=top style='width:78.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Conjunctivitis</span></p>
  <p class=MsoNormal><span lang=EN-GB>Dry eye</span></p>
  <p class=MsoNormal><span lang=EN-GB>Lacrimation increased</span></p>
  <p class=MsoNormal><span lang=EN-GB>Keratoconjunctivitis sicca</span></p>
  <p class=MsoNormal><span lang=EN-GB>Eyelid oedema</span></p>
  <p class=MsoNormal><span lang=EN-GB>Ocular surface disease</span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=81 valign=top style='width:61.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=102 valign=top style='width:76.3pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Cardiac
  disorders<sup> </sup></span></p>
  </td>
  <td width=104 valign=top style='width:78.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Cardiac
  failure</span></p>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Arrhythmia</span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Angina</span></p>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Myocardial
  infarction</span></p>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Coronary
  artery disease</span></p>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Arrhythmia
  supraventricular</span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=81 valign=top style='width:61.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=102 valign=top style='width:76.3pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Vascular
  disorders</span></p>
  </td>
  <td width=104 valign=top style='width:78.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'>Peripheral ischaemia<sup>c</sup></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=81 valign=top style='width:61.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=102 valign=top style='width:76.3pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Respiratory,
  thoracic and mediastinal disorders</span></p>
  </td>
  <td width=104 valign=top style='width:78.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Pulmonary
  embolism Interstitial pneumonitis<sup>bd</sup></span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=81 valign=top style='width:61.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=102 valign=top style='width:76.3pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Gastrointes-tinal
  disorders</span></p>
  </td>
  <td width=104 valign=top style='width:78.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Stomatitis</span></p>
  <p class=MsoNormal><span lang=EN-GB>Anorexia</span></p>
  <p class=MsoNormal><span lang=EN-GB>Vomiting</span></p>
  <p class=MsoNormal><span lang=EN-GB>Diarrhoea</span></p>
  <p class=MsoNormal><span lang=EN-GB>Nausea</span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=mdTblEntry style='page-break-after:auto'><span lang=EN-GB
  style='font-size:11.0pt'>Dyspepsia</span></p>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Constipation</span></p>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Abdominal pain</span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Rectal haemorrhage</span></p>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Gastrointestinal
  haemorrhage</span></p>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Intestinal
  perforation</span></p>
  <p class=Normal11pt style='page-break-after:auto'>Oesophagitis</p>
  <p class=Normal11pt style='page-break-after:auto'>Colitis<sup><span lang=DE>
  e</span></sup></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=81 valign=top style='width:61.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=102 valign=top style='width:76.3pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Hepatobiliary
  disorders</span></p>
  </td>
  <td width=104 valign=top style='width:78.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Aalanine aminotransferase increased</span></p>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Aspartate
  aminotransferase increased</span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Hepatitis</span></p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=81 valign=top style='width:61.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=102 valign=top style='width:76.3pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Skin and
  subcutaneous tissue disorders</span></p>
  </td>
  <td width=104 valign=top style='width:78.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Rash</span></p>
  <p class=MsoNormal><span lang=EN-GB>Skin exfoliation</span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Hyperpigmentation</span></p>
  <p class=MsoNormal><span lang=EN-GB>Pruritus</span></p>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Erythema
  multiforme</span></p>
  <p class=MsoNormal><span lang=EN-GB>Alopecia</span></p>
  <p class=MsoNormal><span lang=EN-GB>Urticaria</span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'>&nbsp;</p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Erythema</span></p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Stevens-Johnson syndrome<sup>b</sup></span></p>
  <p class=MsoNormal><span lang=EN-GB>Toxic epidermal necrolysis<sup>b</sup></span></p>
  <p class=MsoNormal><span lang=EN-GB>Pemphigoid</span></p>
  <p class=MsoNormal><span lang=EN-GB>Dermatitis bullous</span></p>
  <p class=MsoNormal><span lang=EN-GB>Acquired epidermolysis bullosa</span></p>
  <p class=Normal11pt style='page-break-after:auto'><span lang=DE>Erythema-tous
  oedema<sup>f </sup></span></p>
  <p class=MsoNormal><span lang=DE>Pseudocellulitis</span></p>
  <p class=MsoNormal><span lang=DE>Dermatitis</span></p>
  <p class=MsoNormal><span lang=DE>Eczema</span></p>
  <p class=MsoNormal><span lang=EN-GB>Prurigo</span></p>
  </td>
  <td width=81 valign=top style='width:61.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=102 valign=top style='width:76.3pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Renal and
  urinary disorders</span></p>
  </td>
  <td width=104 valign=top style='width:78.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Creatinine clearance decreased</span></p>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Blood creatinine
  increased<sup>e</sup></span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Renal failure</span></p>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Glomerular
  filtration rate decreased</span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=81 valign=top style='width:61.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><a name="_Hlk29467431"><span
  lang=EN-GB>Nephroge-nic diabetes insipidus</span></a></p>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Renal
  tubular necrosis</span></p>
  </td>
 </tr>
 <tr>
  <td width=102 valign=top style='width:76.3pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>General
  disorders and administration site conditions</span></p>
  </td>
  <td width=104 valign=top style='width:78.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Fatigue</span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Pyrexia</span></p>
  <p class=MsoNormal><span lang=EN-GB>Pain</span></p>
  <p class=MsoNormal><span lang=EN-GB>Oedema</span></p>
  <p class=MsoNormal><span lang=EN-GB>Chest pain</span></p>
  <p class=MsoNormal><span lang=EN-GB>Mucosal inflammation</span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'>&nbsp;</p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=81 valign=top style='width:61.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=102 valign=top style='width:76.3pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Investigations</span></p>
  </td>
  <td width=104 valign=top style='width:78.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Gamma-glutamyltransferase
  increased</span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'>&nbsp;</p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=81 valign=top style='width:61.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=102 valign=top style='width:76.3pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Injury,
  poisoning and procedural complications</span></p>
  </td>
  <td width=104 valign=top style='width:78.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'>Radiation oesophagitis</p>
  <p class=Normal11pt style='page-break-after:auto'>Radiation pneumonitis</p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Recall
  pheno-menon</span></p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=81 valign=top style='width:61.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
</table>

<p class=xnormal11pt style='page-break-after:auto'><sup><span lang=EN-GB
style='color:white'>a</span></sup><span lang=EN-GB> with and without
neutropenia </span></p>

<p class=xnormal11pt style='page-break-after:auto'><sup><span lang=EN-GB>b</span></sup><span
lang=EN-GB style='color:black'> </span><span style='color:black'>in some cases
fatal </span></p>

<p class=xnormal11pt style='page-break-after:auto'><sup><span lang=EN-GB>c</span></sup><span
lang=EN-GB> sometimes leading to extremity necrosis </span></p>

<p class=xnormal11pt style='page-break-after:auto'><sup><span lang=EN-GB>d</span></sup><span
lang=EN-GB> </span>with respiratory insufficiency</p>

<p class=xnormal11pt style='page-break-after:auto'><sup><span lang=EN-GB>e</span></sup><span
lang=EN-GB>seen only in combination with cisplatin <br>
<sup>f</sup><span style='color:black'> </span>mainly of the lower limbs</span><span
lang=EN-GB style='color:black'> </span></p>

<p class=MsoNormal style='margin-right:3.7pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB>Reporting of suspected adverse reactions</span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Reporting suspected adverse reactions after authorisation of the
medicinal product is important. It allows continued monitoring of the
benefit/risk balance of the medicinal product. Healthcare professionals are
asked to report any suspected adverse reactions via <span style='background:
lightgrey'>the national reporting system listed in </span></span><span
lang=EN-GB><a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><span
style='background:lightgrey'>Appendix V</span></a></span><span lang=EN-GB>.</span></p>

<p class=MsoNormal style='margin-right:3.7pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.7pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><b><span lang=EN-GB>4.9     Overdose</span></b></p>

<p class=MsoNormal style='margin-right:3.7pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:3.7pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>Reported symptoms of overdose include neutropenia,
anaemia, thrombocytopenia, mucositis, sensory polyneuropathy and rash.
Anticipated complications of overdose include bone marrow suppression as
manifested by neutropenia, thrombocytopenia and anaemia. In addition, infection
with or without fever, diarrhoea, and/or mucositis may be seen. In the event of
suspected overdose, patients should be monitored with blood counts and should
receive supportive therapy as necessary. The use of calcium folinate / folinic
acid in the management of pemetrexed overdose should be considered.</span></p>

<p class=MsoNormal style='margin-right:3.7pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:3.7pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:3.7pt;line-height:normal;page-break-after:
avoid;text-autospace:none'><b><span lang=EN-GB>5.       PHARMACOLOGICAL
PROPERTIES</span></b></p>

<p class=MsoNormal style='margin-right:3.7pt;line-height:normal;page-break-after:
avoid;text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:3.7pt;line-height:normal;page-break-after:
avoid;text-autospace:none'><b><span lang=EN-GB>5.1     Pharmacodynamic
properties</span></b></p>

<p class=MsoNormal style='margin-right:3.7pt;line-height:normal;page-break-after:
avoid;text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;page-break-after:
avoid;text-autospace:none'><span lang=EN-GB>Pharmacotherapeutic group: antineoplastic
agents, folic acid analogues, ATC code: L01BA04.</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>Pemetrexed is a multi-targeted anti-cancer antifolate
agent that exerts its action by disrupting crucial folate-dependent metabolic
processes essential for cell replication.</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;text-autospace:
none'><i><span lang=EN-GB>In vitro</span></i><span lang=EN-GB> studies have
shown that pemetrexed behaves as a multitargeted antifolate by inhibiting
thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide
ribonucleotide formyltransferase (GARFT), which are key folate-dependent
enzymes for the <i>de novo</i> biosynthesis of thymidine and purine
nucleotides. Pemetrexed is transported into cells by both the reduced folate
carrier and membrane folate binding protein transport systems. Once in the
cell, pemetrexed is rapidly and efficiently converted to polyglutamate forms by
the enzyme folylpolyglutamate synthetase. The polyglutamate forms are retained
in cells and are even more potent inhibitors of TS and GARFT. Polyglutamation
is a time- and concentration-dependent process that occurs in tumour cells and,
to a lesser extent, in normal tissues. Polyglutamated metabolites have an
increased intracellular half-life resulting in prolonged active substance action
in malignant cells.</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>The European Medicines Agency has waived the obligation
to submit the results of studies with pemetrexed in all subsets of the
paediatric population in the granted indications (see section&nbsp;4.2).</span></p>

<p class=MsoNormal style='margin-right:3.7pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;text-autospace:
none'><u><span lang=EN-GB>Clinical efficacy</span></u></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;text-autospace:
none'><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><span
lang=EN-GB>Mesothelioma</span></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>EMPHACIS, a multicentre, randomised, single-blind phase 3&nbsp;study
of pemetrexed plus cisplatin versus cisplatin in chemonaive patients with
malignant pleural mesothelioma, has shown that patients treated with pemetrexed
and cisplatin had a clinically meaningful 2.8-month median survival advantage
over patients receiving cisplatin alone.</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>During the study, low-dose folic acid and vitamin B<sub>12</sub>
supplementation was introduced to patients therapy to reduce toxicity. The
primary analysis of this study was performed on the population of all patients
randomly assigned to a treatment arm who received study medicinal product (randomised
and treated). A subgroup analysis was performed on patients who received folic
acid and vitamin B<sub>12</sub> supplementation during the entire course of
study therapy (fully supplemented). The results of these analyses of efficacy
are summarised in the table below:</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>Table 5. Efficacy of pemetrexed plus cisplatin vs. cisplatin in
malignant pleural mesothelioma</span></b></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=637
 style='margin-left:.25pt;border-collapse:collapse'>
 <tr style='height:26.5pt'>
  <td width=244 valign=top style='width:182.8pt;border:solid black 1.0pt;
  padding:0in 0in 0in 0in;height:26.5pt'>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=198 colspan=2 valign=top style='width:148.4pt;border:solid black 1.0pt;
  border-left:none;padding:0in 0in 0in 0in;height:26.5pt'>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><b><span lang=EN-GB>Randomized and
  treated</span></b></p>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><b><span lang=EN-GB>patients</span></b></p>
  </td>
  <td width=195 colspan=2 valign=top style='width:146.55pt;border:solid black 1.0pt;
  border-left:none;padding:0in 0in 0in 0in;height:26.5pt'>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><b><span lang=EN-GB>Fully
  supplemented</span></b></p>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><b><span lang=EN-GB>Patients</span></b></p>
  </td>
 </tr>
 <tr style='height:38.75pt'>
  <td width=244 valign=top style='width:182.8pt;border:solid black 1.0pt;
  border-top:none;padding:0in 0in 0in 0in;height:38.75pt'>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><b><span lang=EN-GB>Efficacy
  parameter</span></b></p>
  </td>
  <td width=102 valign=top style='width:76.4pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in;height:38.75pt'>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><b><span lang=EN-GB>Pemetrexed/</span></b></p>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><b><span lang=EN-GB>cisplatin</span></b></p>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><b><span lang=EN-GB>(N=226)</span></b></p>
  </td>
  <td width=96 valign=top style='width:1.0in;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 0in 0in 0in;
  height:38.75pt'>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><b><span lang=EN-GB>Cisplatin</span></b></p>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><b><span lang=EN-GB>&nbsp;</span></b></p>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><b><span lang=EN-GB>(N=222)</span></b></p>
  </td>
  <td width=102 valign=top style='width:76.6pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in;height:38.75pt'>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><b><span lang=EN-GB>Pemetrexed/</span></b></p>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><b><span lang=EN-GB>cisplatin</span></b></p>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><b><span lang=EN-GB>(N=168)</span></b></p>
  </td>
  <td width=93 valign=top style='width:69.95pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in;height:38.75pt'>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><b><span lang=EN-GB>Cisplatin</span></b></p>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><b><span lang=EN-GB>&nbsp;</span></b></p>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><b><span lang=EN-GB>(N=163)</span></b></p>
  </td>
 </tr>
 <tr style='height:27.95pt'>
  <td width=244 valign=top style='width:182.8pt;border:solid black 1.0pt;
  border-top:none;padding:0in 0in 0in 0in;height:27.95pt'>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><span lang=EN-GB>Median overall
  survival (months)</span></p>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><span lang=EN-GB>(95% CI)</span></p>
  </td>
  <td width=102 valign=top style='width:76.4pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in;height:27.95pt'>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><span lang=EN-GB>12.1</span></p>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><span lang=EN-GB>(10.0 - 14.4)</span></p>
  </td>
  <td width=96 valign=top style='width:1.0in;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 0in 0in 0in;
  height:27.95pt'>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><span lang=EN-GB>9.3</span></p>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><span lang=EN-GB>(7.8 - 10.7)</span></p>
  </td>
  <td width=102 valign=top style='width:76.6pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in;height:27.95pt'>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><span lang=EN-GB>13.3</span></p>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><span lang=EN-GB>(11.4 - 14.9)</span></p>
  </td>
  <td width=93 valign=top style='width:69.95pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in;height:27.95pt'>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><span lang=EN-GB>10.0</span></p>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><span lang=EN-GB>(8.4 - 11.9)</span></p>
  </td>
 </tr>
 <tr style='height:13.45pt'>
  <td width=244 valign=top style='width:182.8pt;border:solid black 1.0pt;
  border-top:none;padding:0in 0in 0in 0in;height:13.45pt'>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><span lang=EN-GB>Log Rank p-value*</span></p>
  </td>
  <td width=198 colspan=2 valign=top style='width:148.4pt;border-top:none;
  border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in;height:13.45pt'>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><span lang=EN-GB>0.020</span></p>
  </td>
  <td width=195 colspan=2 valign=top style='width:146.55pt;border-top:none;
  border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in;height:13.45pt'>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><span lang=EN-GB>0.051</span></p>
  </td>
 </tr>
 <tr style='height:.55in'>
  <td width=244 valign=top style='width:182.8pt;border:solid black 1.0pt;
  border-top:none;padding:0in 0in 0in 0in;height:.55in'>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><span lang=EN-GB>Median time to
  tumour progression</span></p>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><span lang=EN-GB>(months)</span></p>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><span lang=EN-GB>(95% CI)</span></p>
  </td>
  <td width=102 valign=top style='width:76.4pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in;height:.55in'>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><span lang=EN-GB>5.7</span></p>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><span lang=EN-GB>(4.9 - 6.5)</span></p>
  </td>
  <td width=96 valign=top style='width:1.0in;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 0in 0in 0in;
  height:.55in'>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><span lang=EN-GB>3.9</span></p>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><span lang=EN-GB>(2.8 - 4.4)</span></p>
  </td>
  <td width=102 valign=top style='width:76.6pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in;height:.55in'>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><span lang=EN-GB>6.1</span></p>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><span lang=EN-GB>(5.3 - 7.0)</span></p>
  </td>
  <td width=93 valign=top style='width:69.95pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in;height:.55in'>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><span lang=EN-GB>3.9</span></p>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><span lang=EN-GB>(2.8 - 4.5)</span></p>
  </td>
 </tr>
 <tr style='height:13.45pt'>
  <td width=244 valign=top style='width:182.8pt;border:solid black 1.0pt;
  border-top:none;padding:0in 0in 0in 0in;height:13.45pt'>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><span lang=EN-GB>Log Rank p-value*</span></p>
  </td>
  <td width=198 colspan=2 valign=top style='width:148.4pt;border-top:none;
  border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in;height:13.45pt'>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><span lang=EN-GB>0.001</span></p>
  </td>
  <td width=195 colspan=2 valign=top style='width:146.55pt;border-top:none;
  border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in;height:13.45pt'>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><span lang=EN-GB>0.008</span></p>
  </td>
 </tr>
 <tr style='height:28.3pt'>
  <td width=244 valign=top style='width:182.8pt;border:solid black 1.0pt;
  border-top:none;padding:0in 0in 0in 0in;height:28.3pt'>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><span lang=EN-GB>Time to treatment
  failure (months)</span></p>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><span lang=EN-GB>(95% CI)</span></p>
  </td>
  <td width=102 valign=top style='width:76.4pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in;height:28.3pt'>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><span lang=EN-GB>4.5</span></p>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><span lang=EN-GB>(3.9 - 4.9)</span></p>
  </td>
  <td width=96 valign=top style='width:1.0in;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 0in 0in 0in;
  height:28.3pt'>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><span lang=EN-GB>2.7</span></p>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><span lang=EN-GB>(2.1 - 2.9)</span></p>
  </td>
  <td width=102 valign=top style='width:76.6pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in;height:28.3pt'>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><span lang=EN-GB>4.7</span></p>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><span lang=EN-GB>(4.3 - 5.6)</span></p>
  </td>
  <td width=93 valign=top style='width:69.95pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in;height:28.3pt'>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><span lang=EN-GB>2.7</span></p>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><span lang=EN-GB>(2.2 - 3.1)</span></p>
  </td>
 </tr>
 <tr style='height:13.55pt'>
  <td width=244 valign=top style='width:182.8pt;border:solid black 1.0pt;
  border-top:none;padding:0in 0in 0in 0in;height:13.55pt'>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><span lang=EN-GB>Log Rank p-value*</span></p>
  </td>
  <td width=198 colspan=2 valign=top style='width:148.4pt;border-top:none;
  border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in;height:13.55pt'>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><span lang=EN-GB>0.001</span></p>
  </td>
  <td width=195 colspan=2 valign=top style='width:146.55pt;border-top:none;
  border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in;height:13.55pt'>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><span lang=EN-GB>0.001</span></p>
  </td>
 </tr>
 <tr style='height:28.3pt'>
  <td width=244 valign=top style='width:182.8pt;border:solid black 1.0pt;
  border-top:none;padding:0in 0in 0in 0in;height:28.3pt'>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><span lang=EN-GB>Overall response
  rate**</span></p>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><span lang=EN-GB>(95% CI)</span></p>
  </td>
  <td width=102 valign=top style='width:76.4pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in;height:28.3pt'>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><span lang=EN-GB>41.3%</span></p>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><span lang=EN-GB>(34.8 - 48.1)</span></p>
  </td>
  <td width=96 valign=top style='width:1.0in;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 0in 0in 0in;
  height:28.3pt'>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><span lang=EN-GB>16.7%</span></p>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><span lang=EN-GB>(12.0 - 22.2)</span></p>
  </td>
  <td width=102 valign=top style='width:76.6pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in;height:28.3pt'>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><span lang=EN-GB>45.5%</span></p>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><span lang=EN-GB>(37.8 - 53.4)</span></p>
  </td>
  <td width=93 valign=top style='width:69.95pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in;height:28.3pt'>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><span lang=EN-GB>19.6%</span></p>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><span lang=EN-GB>(13.8 - 26.6)</span></p>
  </td>
 </tr>
 <tr style='height:13.45pt'>
  <td width=244 valign=top style='width:182.8pt;border:solid black 1.0pt;
  border-top:none;padding:0in 0in 0in 0in;height:13.45pt'>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><span lang=EN-GB>Fishers exact p-value*</span></p>
  </td>
  <td width=198 colspan=2 valign=top style='width:148.4pt;border-top:none;
  border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in;height:13.45pt'>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><span lang=EN-GB>&lt; 0.001</span></p>
  </td>
  <td width=195 colspan=2 valign=top style='width:146.55pt;border-top:none;
  border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in;height:13.45pt'>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><span lang=EN-GB>&lt; 0.001</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-left:14.2pt;text-indent:-7.1pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>Abbreviation:
CI = confidence interval</span></p>

<p class=MsoNormal style='margin-left:14.2pt;text-indent:-7.1pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>*p-value
refers to comparison between arms.</span></p>

<p class=MsoNormal style='margin-left:14.2pt;text-indent:-7.1pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>**In the
pemetrexed/cisplatin arm, randomized  and treated (N=225) and fully
supplemented (N=167)</span></p>

<p class=MsoNormal style='margin-right:3.7pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>A statistically significant improvement of the
clinically relevant symptoms (pain and dyspnoea) associated with malignant
pleural mesothelioma in the pemetrexed /cisplatin arm (212&nbsp;patients)
versus the cisplatin arm alone (218&nbsp;patients) was demonstrated using the
Lung Cancer Symptom Scale. Statistically significant differences in pulmonary
function tests were also observed. The separation between the treatment arms
was achieved by improvement in lung function in the pemetrexed/cisplatin arm
and deterioration of lung function over time in the control arm.</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>There are limited data in patients with malignant
pleural mesothelioma treated with pemetrexed alone. Pemetrexed at a dose of 500&nbsp;mg/m<sup>2</sup>
was studied as a single-agent in 64&nbsp;chemonaive patients with malignant
pleural mesothelioma. The overall response rate was&nbsp;14.1%.</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;text-autospace:
none'><i><span lang=EN-GB>NSCLC, second-line treatment</span></i></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>A multicentre, randomised, open label phase 3&nbsp;study
of pemetrexed versus docetaxel in patients with locally advanced or metastatic
NSCLC after prior chemotherapy has shown median survival times of
8.3&nbsp;months for patients treated with pemetrexed (Intent To Treat
population n=283) and&nbsp;7.9&nbsp;months for patients treated with docetaxel
(ITT n=288). Prior chemotherapy did not include pemetrexed. An analysis of the
impact of NSCLC histology on the treatment effect on overall survival was in
favour of pemetrexed versus docetaxel for other than predominantly squamous
histologies (n = 399, 9.3&nbsp;versus 8.0 months, adjusted HR=0.78; 95&nbsp;%
CI = 0 .61-1.00, p=0.047) and was in favour of docetaxel for squamous cell
carcinoma histology (n=172,&nbsp;6.2&nbsp;versus 7.4&nbsp;months, adjusted HR =
1.56; 95&nbsp;% CI = 1.08-2.26, p = 0.018). There were no clinically relevant
differences observed for the safety profile of pemetrexed within the histology
subgroups.</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>Limited clinical data from a separate randomized,
Phase&nbsp;3, controlled trial, suggest that efficacy data (overall survival,
progression free survival) for pemetrexed are similar between patients
previously pre-treated with docetaxel (n&nbsp;=&nbsp;41) and patients who did
not receive previous docetaxel treatment (n&nbsp;=&nbsp;540).</span></p>

<p class=MsoNormal style='margin-right:3.7pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal align=center style='text-align:center;line-height:normal;
text-autospace:none'><b><span lang=EN-GB>Table 6. Efficacy of pemetrexed vs
docetaxel in NSCLC - ITT population</span></b></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0
 style='margin-left:.25pt;border-collapse:collapse'>
 <tr style='height:13.2pt'>
  <td width=300 valign=top style='width:225.1pt;border:solid black 1.0pt;
  padding:0in 0in 0in 0in;height:13.2pt'>
  <p class=MsoNormal style='margin-right:3.7pt;line-height:normal;text-autospace:
  none'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=142 valign=top style='width:106.3pt;border:solid black 1.0pt;
  border-left:none;padding:0in 0in 0in 0in;height:13.2pt'>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><b><span lang=EN-GB>Pemetrexed</span></b></p>
  </td>
  <td width=151 colspan=2 valign=top style='width:113.4pt;border:solid black 1.0pt;
  border-left:none;padding:0in 0in 0in 0in;height:13.2pt'>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><b><span lang=EN-GB>Docetaxel</span></b></p>
  </td>
 </tr>
 <tr style='height:38.15pt'>
  <td width=300 rowspan=2 valign=top style='width:225.1pt;border:solid black 1.0pt;
  border-top:none;padding:0in 0in 0in 0in;height:38.15pt'>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><span lang=EN-GB>Survival Time
  (months)</span></p>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:3.7pt;
  margin-bottom:0in;margin-left:.5in;margin-bottom:.0001pt;text-align:center;
  text-indent:-.25in;line-height:normal;text-autospace:none'><span lang=EN-GB
  style='font-family:Wingdings'>§<span style='font:7.0pt "Times New Roman"'> </span></span><span
  lang=EN-GB>Median (m)</span></p>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:3.7pt;
  margin-bottom:0in;margin-left:.5in;margin-bottom:.0001pt;text-align:center;
  text-indent:-.25in;line-height:normal;text-autospace:none'><span lang=EN-GB
  style='font-family:Wingdings'>§<span style='font:7.0pt "Times New Roman"'> </span></span><span
  lang=EN-GB>95 % CI for median</span></p>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:3.7pt;
  margin-bottom:0in;margin-left:.5in;margin-bottom:.0001pt;text-align:center;
  text-indent:-.25in;line-height:normal;text-autospace:none'><span lang=EN-GB
  style='font-family:Wingdings'>§<span style='font:7.0pt "Times New Roman"'> </span></span><span
  lang=EN-GB>HR</span></p>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:3.7pt;
  margin-bottom:0in;margin-left:.5in;margin-bottom:.0001pt;text-align:center;
  text-indent:-.25in;line-height:normal;text-autospace:none'><span lang=EN-GB
  style='font-family:Wingdings'>§<span style='font:7.0pt "Times New Roman"'> </span></span><span
  lang=EN-GB>95 % CI for HR</span></p>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:3.7pt;
  margin-bottom:0in;margin-left:.5in;margin-bottom:.0001pt;text-align:center;
  text-indent:-.25in;line-height:normal;text-autospace:none'><span lang=EN-GB
  style='font-family:Wingdings'>§<span style='font:7.0pt "Times New Roman"'> </span></span><span
  lang=EN-GB>Non-inferiority p-value (HR)</span></p>
  </td>
  <td width=142 valign=top style='width:106.3pt;border:none;padding:0in 0in 0in 0in;
  height:38.15pt'>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><span lang=EN-GB>(n = 283)</span></p>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><span lang=EN-GB>8.3</span></p>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><span lang=EN-GB>(7.0 - 9.4)</span></p>
  </td>
  <td width=151 colspan=2 valign=top style='width:113.4pt;border:none;
  border-right:solid black 1.0pt;padding:0in 0in 0in 0in;height:38.15pt'>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><span lang=EN-GB>(n = 288)</span></p>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><span lang=EN-GB>7.9</span></p>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><span lang=EN-GB>(6.3 - 9.2)</span></p>
  </td>
 </tr>
 <tr style='height:38.3pt'>
  <td width=293 colspan=3 valign=top style='width:219.7pt;border-top:none;
  border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in;height:38.3pt'>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><span lang=EN-GB>0.99</span></p>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><span lang=EN-GB>(.82 - 1.20)</span></p>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><span lang=EN-GB>.226</span></p>
  </td>
 </tr>
 <tr style='height:19.15pt'>
  <td width=300 rowspan=2 valign=top style='width:225.1pt;border:solid black 1.0pt;
  border-top:none;padding:0in 0in 0in 0in;height:19.15pt'>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><b><span lang=EN-GB>Progression free
  survival (months)</span></b></p>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:3.7pt;
  margin-bottom:0in;margin-left:.5in;margin-bottom:.0001pt;text-align:center;
  text-indent:-.25in;line-height:normal;text-autospace:none'><span lang=EN-GB
  style='font-family:Wingdings'>§<span style='font:7.0pt "Times New Roman"'> </span></span><span
  lang=EN-GB>Median</span></p>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:3.7pt;
  margin-bottom:0in;margin-left:.5in;margin-bottom:.0001pt;text-align:center;
  text-indent:-.25in;line-height:normal;text-autospace:none'><span lang=EN-GB
  style='font-family:Wingdings'>§<span style='font:7.0pt "Times New Roman"'> </span></span><span
  lang=EN-GB>HR (95 % CI)</span></p>
  </td>
  <td width=146 colspan=2 valign=top style='width:109.85pt;border:none;
  padding:0in 0in 0in 0in;height:19.15pt'>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><span lang=EN-GB>(n = 283)</span></p>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><span lang=EN-GB>2.9</span></p>
  </td>
  <td width=146 valign=top style='width:109.85pt;border:none;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in;height:19.15pt'>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><span lang=EN-GB>(n = 288)</span></p>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><span lang=EN-GB>2.9</span></p>
  </td>
 </tr>
 <tr style='height:19.1pt'>
  <td width=293 colspan=3 valign=top style='width:219.7pt;border-top:none;
  border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in;height:19.1pt'>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><span lang=EN-GB>0.97 (.82  1.16)</span></p>
  </td>
 </tr>
 <tr style='height:19.15pt'>
  <td width=300 rowspan=2 valign=top style='width:225.1pt;border:solid black 1.0pt;
  border-top:none;padding:0in 0in 0in 0in;height:19.15pt'>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><b><span lang=EN-GB>Time to treatment
  failure (TTTF  months)</span></b></p>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:3.7pt;
  margin-bottom:0in;margin-left:.5in;margin-bottom:.0001pt;text-align:center;
  text-indent:-.25in;line-height:normal;text-autospace:none'><span lang=EN-GB
  style='font-family:Wingdings'>§<span style='font:7.0pt "Times New Roman"'> </span></span><span
  lang=EN-GB>Median</span></p>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:3.7pt;
  margin-bottom:0in;margin-left:.5in;margin-bottom:.0001pt;text-align:center;
  text-indent:-.25in;line-height:normal;text-autospace:none'><span lang=EN-GB
  style='font-family:Wingdings'>§<span style='font:7.0pt "Times New Roman"'> </span></span><span
  lang=EN-GB>HR (95 % CI)</span></p>
  </td>
  <td width=146 colspan=2 valign=top style='width:109.85pt;border:none;
  padding:0in 0in 0in 0in;height:19.15pt'>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><span lang=EN-GB>(n = 283)</span></p>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><span lang=EN-GB>2.3</span></p>
  </td>
  <td width=146 valign=top style='width:109.85pt;border:none;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in;height:19.15pt'>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><span lang=EN-GB>(n = 288)</span></p>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><span lang=EN-GB>2.1</span></p>
  </td>
 </tr>
 <tr style='height:19.1pt'>
  <td width=293 colspan=3 valign=top style='width:219.7pt;border-top:none;
  border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in;height:19.1pt'>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><span lang=EN-GB>0.84 (.71 - .997)</span></p>
  </td>
 </tr>
 <tr style='height:38.5pt'>
  <td width=300 valign=top style='width:225.1pt;border:solid black 1.0pt;
  border-top:none;padding:0in 0in 0in 0in;height:38.5pt'>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><b><span lang=EN-GB>Response (n:
  qualified for response)</span></b></p>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:3.7pt;
  margin-bottom:0in;margin-left:.5in;margin-bottom:.0001pt;text-align:center;
  text-indent:-.25in;line-height:normal;text-autospace:none'><span lang=EN-GB
  style='font-family:Wingdings'>§<span style='font:7.0pt "Times New Roman"'> </span></span><span
  lang=EN-GB>Response rate (%) (95 % CI)</span></p>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:3.7pt;
  margin-bottom:0in;margin-left:.5in;margin-bottom:.0001pt;text-align:center;
  text-indent:-.25in;line-height:normal;text-autospace:none'><span lang=EN-GB
  style='font-family:Wingdings'>§<span style='font:7.0pt "Times New Roman"'> </span></span><span
  lang=EN-GB>Stable disease (%)</span></p>
  </td>
  <td width=142 valign=top style='width:106.3pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in;height:38.5pt'>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><span lang=EN-GB>(n = 264)</span></p>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><span lang=EN-GB>9.1 (5.9 - 13.2)</span></p>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><span lang=EN-GB>45.8</span></p>
  </td>
  <td width=151 colspan=2 valign=top style='width:113.4pt;border-top:none;
  border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in;height:38.5pt'>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><span lang=EN-GB>(n = 274)</span></p>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><span lang=EN-GB>8.8 (5.7 - 12.8)</span></p>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><span lang=EN-GB>46.4</span></p>
  </td>
 </tr>
 <tr height=0>
  <td width=300 style='border:none'></td>
  <td width=142 style='border:none'></td>
  <td width=5 style='border:none'></td>
  <td width=146 style='border:none'></td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB style='font-size:10.0pt'>Abbreviations:  CI = confidence interval;
HR = hazard ratio; ITT = intent to treat; n = total population size.</span></p>

<p class=MsoNormal style='margin-right:3.7pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:3.7pt;line-height:normal;text-autospace:
none'><i><span lang=EN-GB>NSCLC, first-line treatment</span></i></p>

<p class=MsoNormal style='margin-right:3.7pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>A multicentre, randomised, open-label, Phase
3&nbsp;study of pemetrexed plus cisplatin versus gemcitabine plus cisplatin in
chemonaive patients with locally advanced or metastatic (Stage IIIb or IV)
non-small cell lung cancer (NSCLC) showed that pemetrexed plus cisplatin
(Intent-To-Treat [ITT] population n=862) met its primary endpoint and showed
similar clinical efficacy as gemcitabine plus cisplatin (ITT n=863) in overall
survival (adjusted hazard ratio 0.94; 95&nbsp;%&nbsp;CI=0.84-1.05). All
patients included in this study had an ECOG performance status&nbsp;0&nbsp;or&nbsp;1.</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>The primary efficacy analysis was based on the ITT
population. Sensitivity analyses of main efficacy endpoints were also assessed
on the Protocol Qualified (PQ) population. The efficacy analyses using PQ
population are consistent with the analyses for the ITT population and support
the non-inferiority of AC versus GC.</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>Progression free survival (PFS) and overall response
rate were similar between treatment arms: median PFS was 4.8&nbsp;months for
pemetrexed plus cisplatin versus 5.1&nbsp;months for gemcitabine plus cisplatin
(adjusted hazard ratio 1.04; 95&nbsp;% CI = 0.94-1.15), and overall response
rate was 30.6% (95&nbsp;% CI = 27.3-33.9) for pemetrexed plus cisplatin versus
28.2% (95&nbsp;%&nbsp;CI&nbsp;=&nbsp;25.0-31.4) for gemcitabine plus cisplatin.
PFS data were partially confirmed by an independent review
(400/1725&nbsp;patients were randomly selected for review). The analysis of the
impact of NSCLC histology on overall survival demonstrated clinically relevant
differences in survival according to histology, see table below.</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal align=center style='text-align:center;line-height:normal;
text-autospace:none'><b><span lang=EN-GB>Table 7. Efficacy of pemetrexed +
cisplatin vs. gemcitabine + cisplatin in first-line non-small cell lung cancer
 ITT population and histology subgroups.</span></b></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0
 style='margin-left:.25pt;border-collapse:collapse'>
 <tr style='height:26.4pt'>
  <td width=115 rowspan=2 valign=top style='width:85.9pt;border:solid black 1.0pt;
  padding:0in 0in 0in 0in;height:26.4pt'>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><b><span lang=EN-GB>ITT population
  and histology subgroups</span></b></p>
  </td>
  <td width=327 colspan=4 valign=top style='width:245.4pt;border:solid black 1.0pt;
  border-left:none;padding:0in 0in 0in 0in;height:26.4pt'>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><b><span lang=EN-GB>Median overall
  survival in months</span></b></p>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><b><span lang=EN-GB>(95% CI)</span></b></p>
  </td>
  <td width=91 rowspan=2 valign=top style='width:.95in;border:solid black 1.0pt;
  border-left:none;padding:0in 0in 0in 0in;height:26.4pt'>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><b><span lang=EN-GB>Adjusted hazard
  ratio (HR)</span></b></p>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><b><span lang=EN-GB>(95% CI)</span></b></p>
  </td>
  <td width=86 rowspan=2 valign=top style='width:64.7pt;border:solid black 1.0pt;
  border-left:none;padding:0in 0in 0in 0in;height:26.4pt'>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><b><span lang=EN-GB>&nbsp;</span></b></p>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><b><span lang=EN-GB>Superiority p-value</span></b></p>
  </td>
 </tr>
 <tr style='height:26.4pt'>
  <td width=168 colspan=2 valign=top style='width:125.75pt;border-top:none;
  border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in;height:26.4pt'>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><b><span lang=EN-GB>Pemetrexed +
  cisplatin</span></b></p>
  </td>
  <td width=160 colspan=2 valign=top style='width:119.65pt;border-top:none;
  border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in;height:26.4pt'>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><b><span lang=EN-GB>Gemcitabine +</span></b></p>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><b><span lang=EN-GB>cisplatin</span></b></p>
  </td>
 </tr>
 <tr style='height:28.1pt'>
  <td width=115 valign=top style='width:85.9pt;border:solid black 1.0pt;
  border-top:none;padding:0in 0in 0in 0in;height:28.1pt'>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><span lang=EN-GB>ITT population</span></p>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><span lang=EN-GB>(N = 1725)</span></p>
  </td>
  <td width=91 valign=top style='width:68.05pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in;height:28.1pt'>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><span lang=EN-GB>10.3</span></p>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><span lang=EN-GB>(9.8  11.2)</span></p>
  </td>
  <td width=77 valign=top style='width:57.7pt;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 0in 0in 0in;
  height:28.1pt'>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><span lang=EN-GB>N=862</span></p>
  </td>
  <td width=92 valign=top style='width:69.25pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in;height:28.1pt'>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><span lang=EN-GB>10.3</span></p>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><span lang=EN-GB>(9.6  10.9)</span></p>
  </td>
  <td width=67 valign=top style='width:.7in;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 0in 0in 0in;
  height:28.1pt'>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><span lang=EN-GB>N=863</span></p>
  </td>
  <td width=91 valign=top style='width:.95in;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 0in 0in 0in;
  height:28.1pt'>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'>0.94a</p>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'>(0.84  1.05)<span lang=EN-GB> (0.84
   1.05)</span></p>
  </td>
  <td width=86 valign=top style='width:64.7pt;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 0in 0in 0in;
  height:28.1pt'>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><span lang=EN-GB>0.259</span></p>
  </td>
 </tr>
 <tr style='height:26.4pt'>
  <td width=115 valign=top style='width:85.9pt;border:solid black 1.0pt;
  border-top:none;padding:0in 0in 0in 0in;height:26.4pt'>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><span lang=EN-GB>Adenocarcinoma</span></p>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><span lang=EN-GB>(N=847)</span></p>
  </td>
  <td width=91 valign=top style='width:68.05pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in;height:26.4pt'>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><span lang=EN-GB>12.6 (10.7  13.6)</span></p>
  </td>
  <td width=77 valign=top style='width:57.7pt;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 0in 0in 0in;
  height:26.4pt'>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><span lang=EN-GB>N=436</span></p>
  </td>
  <td width=92 valign=top style='width:69.25pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in;height:26.4pt'>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><span lang=EN-GB>10.9</span></p>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><span lang=EN-GB>(10.2  11.9)</span></p>
  </td>
  <td width=67 valign=top style='width:.7in;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 0in 0in 0in;
  height:26.4pt'>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><span lang=EN-GB>N=411</span></p>
  </td>
  <td width=91 valign=top style='width:.95in;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 0in 0in 0in;
  height:26.4pt'>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><span lang=EN-GB>0.84</span></p>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><span lang=EN-GB>(0.710.99)</span></p>
  </td>
  <td width=86 valign=top style='width:64.7pt;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 0in 0in 0in;
  height:26.4pt'>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><span lang=EN-GB>0.033</span></p>
  </td>
 </tr>
 <tr style='height:26.4pt'>
  <td width=115 valign=top style='width:85.9pt;border:solid black 1.0pt;
  border-top:none;padding:0in 0in 0in 0in;height:26.4pt'>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><span lang=EN-GB>Large cell</span></p>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><span lang=EN-GB>(N=153)</span></p>
  </td>
  <td width=91 valign=top style='width:68.05pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in;height:26.4pt'>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><span lang=EN-GB>10.4</span></p>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><span lang=EN-GB>(8.6  14.1)</span></p>
  </td>
  <td width=77 valign=top style='width:57.7pt;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 0in 0in 0in;
  height:26.4pt'>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><span lang=EN-GB>N=76</span></p>
  </td>
  <td width=92 valign=top style='width:69.25pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in;height:26.4pt'>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><span lang=EN-GB>6.7</span></p>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><span lang=EN-GB>(5.5  9.0)</span></p>
  </td>
  <td width=67 valign=top style='width:.7in;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 0in 0in 0in;
  height:26.4pt'>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><span lang=EN-GB>N=77</span></p>
  </td>
  <td width=91 valign=top style='width:.95in;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 0in 0in 0in;
  height:26.4pt'>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><span lang=EN-GB>0.67</span></p>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><span lang=EN-GB>(0.480.96)</span></p>
  </td>
  <td width=86 valign=top style='width:64.7pt;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 0in 0in 0in;
  height:26.4pt'>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><span lang=EN-GB>0.027</span></p>
  </td>
 </tr>
 <tr style='height:26.4pt'>
  <td width=115 valign=top style='width:85.9pt;border:solid black 1.0pt;
  border-top:none;padding:0in 0in 0in 0in;height:26.4pt'>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><span lang=EN-GB>Other</span></p>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><span lang=EN-GB>(N=252)</span></p>
  </td>
  <td width=91 valign=top style='width:68.05pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in;height:26.4pt'>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><span lang=EN-GB>8.6</span></p>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><span lang=EN-GB>(6.8  10.2)</span></p>
  </td>
  <td width=77 valign=top style='width:57.7pt;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 0in 0in 0in;
  height:26.4pt'>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><span lang=EN-GB>N=106</span></p>
  </td>
  <td width=92 valign=top style='width:69.25pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in;height:26.4pt'>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><span lang=EN-GB>9.2</span></p>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><span lang=EN-GB>(8.1  10.6)</span></p>
  </td>
  <td width=67 valign=top style='width:.7in;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 0in 0in 0in;
  height:26.4pt'>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><span lang=EN-GB>N=146</span></p>
  </td>
  <td width=91 valign=top style='width:.95in;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 0in 0in 0in;
  height:26.4pt'>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><span lang=EN-GB>1.08</span></p>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><span lang=EN-GB>(0.811.45)</span></p>
  </td>
  <td width=86 valign=top style='width:64.7pt;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 0in 0in 0in;
  height:26.4pt'>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><span lang=EN-GB>0.586</span></p>
  </td>
 </tr>
 <tr style='height:26.5pt'>
  <td width=115 valign=top style='width:85.9pt;border:solid black 1.0pt;
  border-top:none;padding:0in 0in 0in 0in;height:26.5pt'>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><span lang=EN-GB>Squamous cell</span></p>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><span lang=EN-GB>(N=473)</span></p>
  </td>
  <td width=91 valign=top style='width:68.05pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in;height:26.5pt'>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><span lang=EN-GB>9.4</span></p>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><span lang=EN-GB>(8.4  10.2)</span></p>
  </td>
  <td width=77 valign=top style='width:57.7pt;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 0in 0in 0in;
  height:26.5pt'>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><span lang=EN-GB>N=244</span></p>
  </td>
  <td width=92 valign=top style='width:69.25pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in;height:26.5pt'>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><span lang=EN-GB>10.8</span></p>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><span lang=EN-GB>(9.5  12.1)</span></p>
  </td>
  <td width=67 valign=top style='width:.7in;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 0in 0in 0in;
  height:26.5pt'>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><span lang=EN-GB>N=229</span></p>
  </td>
  <td width=91 valign=top style='width:.95in;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 0in 0in 0in;
  height:26.5pt'>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><span lang=EN-GB>1.23</span></p>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><span lang=EN-GB>(1.001.51)</span></p>
  </td>
  <td width=86 valign=top style='width:64.7pt;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 0in 0in 0in;
  height:26.5pt'>
  <p class=MsoNormal align=center style='margin-right:3.7pt;text-align:center;
  line-height:normal;text-autospace:none'><span lang=EN-GB>0.050</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB style='font-size:10.0pt;color:white'>Abbreviations:  CI = confidence
interval; ITT = intent-to-treat; N = total population size.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><sup><span
lang=EN-GB style='font-size:10.0pt'>a</span></sup><span lang=EN-GB
style='font-size:10.0pt'> Statistically significant for noninferiority, with
the entire confidence interval for HR well below the 1.17645 noninferiority
margin (p &lt;0.001).</span></p>

<p class=MsoNormal style='margin-right:3.7pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:3.7pt;line-height:normal;text-autospace:
none'><b><span lang=EN-GB>Kaplan Meier plots of overall survival by histology</span></b></p>

<p class=MsoNormal style='margin-right:3.7pt;line-height:normal;text-autospace:
none'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:3.7pt;line-height:normal;text-autospace:
none'><span lang=DE><img border=0 width=567 height=250 id="Picture 1"
src="Armisarte%20R-22%20PI%20-%20clean_files/image001.jpg"></span></p>

<p class=MsoNormal style='margin-right:10.45pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>There were no clinically relevant differences observed
for the safety profile of pemetrexed plus cisplatin within the histology
subgroups.</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>Patients treated with pemetrexed and cisplatin required
fewer transfusions (16.4% versus 28.9%, p&lt;0.001), red blood cell
transfusions (16.1% versus 27.3%, p&lt;0.001) and platelet transfusions (1.8%
versus 4.5%, p=0.002). Patients also required lower administration of
erythropoietin/darbopoietin (10.4% versus 18.1%, p&lt;0.001), G-CSF/GM-CSF
(3.1% versus 6.1%, p=0.004), and iron preparations (4.3% versus 7.0%, p=0.021)<i>.</i></span></p>

<p class=MsoNormal style='margin-right:-1.0pt;line-height:normal;text-autospace:
none'><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='margin-right:-1.0pt;line-height:normal;text-autospace:
none'><i><span lang=EN-GB>NSCLC, maintenance treatment</span></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-1.0pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>JMEN</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>A multicentre, randomised, double-blind,
placebo-controlled Phase 3 study (JMEN), compared the efficacy and safety of
maintenance treatment with pemetrexed plus best supportive care (BSC) (n=441)
with that of placebo plus BSC (n=222) in patients with locally advanced (Stage
IIIB) or metastatic (Stage IV) Non Small Cell Lung Cancer (NSCLC) who did not
progress after 4&nbsp;cycles of first line doublet therapy containing Cisplatin
or Carboplatin in combination with Gemcitabine, Paclitaxel, or Docetaxel. First
line doublet therapy containing pemetrexed was not included. All patients
included in this study had an ECOG performance status&nbsp;0&nbsp;or&nbsp;1.
Patients received maintenance treatment until disease progression. Efficacy and
safety were measured from the time of randomisation after completion of first
line (induction) therapy. Patients received a median of 5&nbsp;cycles of
maintenance treatment with pemetrexed and 3.5&nbsp;cycles of placebo. A total
of 213&nbsp;patients (48.3%) completed &#8805; 6&nbsp;cycles and a total of 103&nbsp;patients
(23.4%) completed &#8805;&nbsp;10 cycles of treatment with pemetrexed.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>The study met its primary endpoint and showed a
statistically significant improvement in PFS in the pemetrexed arm over the
placebo arm (n=581, independently reviewed population; median of
4.0&nbsp;months and 2.0&nbsp;months, respectively) (hazard ratio=0.60, 95%
CI=0.49-0.73, p&lt;0.00001). The independent review of patient scans confirmed
the findings of the investigator assessment of PFS. The median OS for the
overall population (n=663) was 13.4&nbsp;months for the pemetrexed arm and
10.6&nbsp;months for the placebo arm, hazard ratio=0.79 (95% CI=0.65-0.95,
p=0.01192).</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>Consistent with other pemetrexed studies, a difference
in efficacy according to NSCLC histology was observed in JMEN. For patients
with NSCLC other than predominantly squamous cell histology (n=430,
independently reviewed population) median PFS was 4.4&nbsp;months for the
pemetrexed arm and 1.8&nbsp;months for the placebo arm, hazard ratio=0.47&nbsp;(95%
CI=0.37-0.60, p=0.00001). The median OS for patients with NSCLC other than
predominantly squamous cell histology (n=481) was 15.5&nbsp;months for the
pemetrexed arm and 10.3&nbsp;months for the placebo arm, hazard
ratio=0.70&nbsp;(95&nbsp;%&nbsp;CI&nbsp;=&nbsp;0.56-0.88, p&nbsp;=&nbsp;0.002).
Including the induction phase the median OS for patients with NSCLC other than
predominantly squamous cell histology was 18.6&nbsp;months for the pemetrexed
arm and 13.6&nbsp;months for the placebo arm, hazard
ratio=0.71&nbsp;(95&nbsp;%&nbsp;CI=0.56-0.88, p=0.002).</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>The PFS and OS results in patients with squamous cell
histology suggested no advantage for pemetrexed over placebo.</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>There were no clinically relevant differences observed
for the safety profile of pemetrexed within the histology subgroups.</span></p>

<p class=MsoNormal style='margin-right:-1.0pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-1.0pt;line-height:normal;text-autospace:
none'><b><span lang=EN-GB>JMEN: Kaplan Meier plots of progression-free survival
(PFS) and overall survival pemetrexed versus placebo in patients with NSCLC
other than predominantly squamous cell histology:</span></b></p>

<p class=MsoNormal style='margin-right:-1.0pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-1.0pt;line-height:normal;text-autospace:
none'><span lang=DE><img border=0 width=567 height=250 id="Picture 2"
src="Armisarte%20R-22%20PI%20-%20clean_files/image002.jpg"></span></p>

<p class=MsoNormal style='margin-right:-1.0pt;line-height:normal;text-autospace:
none'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>PARAMOUNT</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>A multicentre, randomised, double-blind,
placebo-controlled Phase 3&nbsp;study (PARAMOUNT), compared the efficacy and
safety of continuation maintenance treatment with pemetrexed plus BSC (n=359)
with that of placebo plus BSC (n=180) in patients with locally advanced (Stage
IIIB) or metastatic (Stage IV) NSCLC other than predominantly squamous cell
histology who did not progress after 4&nbsp;cycles of first line doublet
therapy of pemetrexed in combination with cisplatin. Of the 939&nbsp;patients
treated with pemetrexed plus cisplatin induction, 539&nbsp;patients were
randomised to maintenance treatment with pemetrexed or placebo. Of the
randomised patients, 44.9% had a complete/partial response and 51.9% had a
response of stable disease to pemetrexed plus cisplatin induction. Patients
randomised to maintenance treatment were required to have an ECOG performance
status 0 or 1. The median time from the start of pemetrexed plus cisplatin
induction therapy to the start of maintenance treatment was 2.96&nbsp;months on
both the pemetrexed arm and the placebo arm. Randomised patients received
maintenance treatment until disease progression. Efficacy and safety were
measured from the time of randomisation after completion of first line
(induction) therapy. Patients received a median of 4&nbsp;cycles of maintenance
treatment with pemetrexed and 4&nbsp;cycles of placebo. A total of
169&nbsp;patients (47.1&nbsp;%) completed &#8805;&nbsp;6&nbsp;cycles
maintenance treatment with pemetrexed, representing at least 10&nbsp;total
cycles of pemetrexed.</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>The study met its primary endpoint and showed a
statistically significant improvement in PFS in the pemetrexed arm over the
placebo arm (n=472, independently reviewed population; median of
3.9&nbsp;months and 2.6&nbsp;months, respectively) (hazard ratio=0.64,
95&nbsp;% CI=0.51-0.81, p=0.0002). The independent review of patient scans
confirmed the findings of the investigator assessment of PFS. For randomised
patients, as measured from the start of pemetrexed plus cisplatin first line
induction treatment, the median investigator-assessed PFS was 6.9&nbsp;months
for the pemetrexed arm and&nbsp;5.6&nbsp;months for the placebo arm (hazard
ratio = 0.59 95&nbsp;% CI=0.47-0.74).</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>Following pemetrexed plus cisplatin induction (4&nbsp;cycles),
treatment with pemetrexed was statistically superior to placebo for OS (median
13.9&nbsp;months versus 11.0&nbsp;months, hazard&nbsp;ratio=0.78,
95&nbsp;%CI=0.64-0.96, p=0.0195). At the time of this final survival analysis,
28.7% of patients were alive or lost to follow up on the pemetrexed arm versus
21.7% on the placebo arm. The relative treatment effect of pemetrexed was internally
consistent across subgroups (including disease stage, induction response, ECOG
PS, smoking status, gender, histology and age) and similar to that observed in
the unadjusted OS and PFS analyses. The 1&nbsp;year and 2&nbsp;year survival
rates for patients on pemetrexed were 58% and 32% respectively, compared to 45%
and 21% for patients on placebo. From the start of pemetrexed plus cisplatin
first line induction treatment, the median OS of patients was 16.9&nbsp;months
for the pemetrexed arm and 14.0&nbsp;months for the placebo arm (hazard
ratio=0.78, 95&nbsp;% CI=0.64-0.96). The percentage of patients that received
post study treatment was 64.3% for pemetrexed and 71.7% for placebo.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.45pt;margin-bottom:
0in;margin-left:5.9pt;margin-bottom:.0001pt;line-height:normal;text-autospace:
none'><b><span lang=EN-GB>PARAMOUNT:Kaplan Meier plot of progression-free
survival (PFS) and overall survival (OS) for continuation pemetrexed
maintenance versus placebo in patients with NSCLC other than predominantly
squamous cell histology (measured from randomisation)</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.45pt;margin-bottom:
0in;margin-left:5.9pt;margin-bottom:.0001pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.45pt;margin-bottom:
0in;margin-left:5.9pt;margin-bottom:.0001pt;line-height:normal;text-autospace:
none'><span lang=DE><img border=0 width=567 height=259 id="Picture 3"
src="Armisarte%20R-22%20PI%20-%20clean_files/image003.jpg"></span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>The pemetrexed maintenance safety profiles from the two
studies JMEN and PARAMOUNT were similar.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>5.2     Pharmacokinetic properties</span></b></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>The pharmacokinetic properties of pemetrexed following
single-agent administration have been evaluated in 426&nbsp;cancer patients
with a variety of solid tumours at doses ranging from
0.2&nbsp;to&nbsp;838&nbsp;mg/m<sup>2</sup> infused over a 10&nbsp;minute period.
Pemetrexed has a steady-state volume of distribution of 9&nbsp;l/m<sup>2</sup>.
<i>In vitro </i>studies indicate that pemetrexed is approximately 81% bound to
plasma proteins. Binding was not notably affected by varying degrees of renal
impairment. Pemetrexed undergoes limited hepatic metabolism. Pemetrexed is
primarily eliminated in the urine, with 70% to 90% of the administered dose
being recovered unchanged in urine within the first 24&nbsp;hours following
administration. <i>In vitro </i>studies indicate that pemetrexed is actively secreted
by OAT3 (organic anion transporter. Pemetrexed total systemic clearance is
91.8&nbsp;ml/min and the elimination half-life from plasma is 3.5&nbsp;hours in
patients with normal renal function (creatinine clearance of 90&nbsp;ml/min).
Between patient variability in clearance is moderate at 19.3%. Pemetrexed total
systemic exposure (AUC) and maximum plasma concentration increase
proportionally with dose. The pharmacokinetics of pemetrexed are consistent
over multiple treatment cycles.</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>The pharmacokinetic properties of pemetrexed are not
influenced by concurrently administered cisplatin. Oral folic acid and
intramuscular vitamin B<sub>12</sub> supplementation do not affect the
pharmacokinetics of pemetrexed.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>5.3     Preclinical safety data</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>Administration of pemetrexed to pregnant mice resulted
in decreased foetal viability, decreased foetal weight, incomplete ossification
of some skeletal structures and cleft palate.</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>Administration of pemetrexed to male mice resulted in
reproductive toxicity characterised by reduced fertility rates and testicular
atrophy. In a study conducted in beagle dog by intravenous bolus injection for
9&nbsp;months, testicular findings (degeneration/necrosis of the seminiferous
epithelium) have been observed. This suggests that pemetrexed may impair male
fertility. Female fertility was not investigated.</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>Pemetrexed was not mutagenic in either the <i>in vitro </i>chromosome
aberration test in Chinese hamster ovary cells, or the Ames test. Pemetrexed
has been shown to be clastogenic in the <i>in vivo </i>micronucleus test in the
mouse.</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>Studies to assess the carcinogenic potential of
pemetrexed have not been conducted.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>6.       PHARMACEUTICAL PARTICULARS</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>6.1     List of excipients</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Trometamol (for
pH adjustment)</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Citric acid</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Methionine</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Water for
injections</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>6.2     Incompatibilities</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>Pemetrexed is physically incompatible with diluents
containing calcium, including lactated Ringers injection and Ringers
injection. In the absence of other compatibility studies this medicinal product
must not be mixed with other medicinal products.</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>Armisarte contains trometamol as an excipient.
Trometamol is incompatible with cisplatin resulting in degradation of
cisplatin. </span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>Intravenous lines should be flushed after administration
of Armisarte.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>6.3     Shelf life</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-1.0pt;line-height:normal;text-autospace:
none'><u><span lang=EN-GB>Unopened vial</span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>18 months.</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;text-autospace:
none'><u><span lang=EN-GB>Diluted solution</span></u></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>Chemical and physical in-use stability of infusion
solution of pemetrexed was demonstrated for 24&nbsp;hours at room temperature
and 7&nbsp;days at refrigerated temperature. From a microbiological point of
view, the product should be used immediately. If not used immediately, in-use
storage times and conditions prior to use are the responsibility of the user
and would not be longer than 24&nbsp;hours at 2&nbsp;°C-8&nbsp;°C, unless
dilution has taken place in controlled and validated aseptic conditions.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>6.4     Special precautions for storage</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal'><span
lang=EN-GB>Store and transport refrigerated (2&nbsp;°C-8&nbsp;°C).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Do not freeze.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Keep the vial in
the outer carton in order to protect from light.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>For storage
conditions after dilution of the medicinal product, see section&nbsp;6.3.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>6.5     Nature and contents of container</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Colourless glass
vial (type I) with type I rubber (bromobutyl) serum stopper and an aluminium
cap with polypropylene disk. Vials may or may not be sheathed in a protective
sleeve.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:yellow'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Pack sizes</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>1 x 4&nbsp;ml
vial (100 mg/4 ml)</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>1 x 20&nbsp;ml
vial (500 mg/20 ml)</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>1 x 34&nbsp;ml
vial (850 mg/34 ml)</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>1 x 40&nbsp;ml
vial (1000 mg/40 ml)</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Not all pack
sizes may be marketed.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>6.6     Special precautions for disposal and other
handling</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.05pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-27.15pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>1.      Use aseptic technique
during dilution of pemetrexed for intravenous infusion administration.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.05pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-27.15pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.05pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-27.15pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>2.      Calculate the dose and the
number of Armisarte vials needed.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.05pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-27.15pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.05pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-27.15pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>3.      Armisarte must only be
diluted<span style='color:black'> with 5%&nbsp;glucose solution, without
preservative</span>. The appropriate volume of pemetrexed concentrate must be
diluted <span style='color:black'>to 100&nbsp;ml with 5% glucose solution</span>
and administered as an intravenous infusion over 10&nbsp;minutes. </span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.05pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-27.15pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.05pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-27.15pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>4.      Pemetrexed infusion
solutions prepared as directed above are compatible with polyvinyl chloride and
polyolefin lined administration sets and infusion bags.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.05pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-27.15pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.05pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-27.15pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>5.      Parenteral medicinal
products must be inspected visually for particulate matter and discolouration
prior to administration. If particulate matter is observed, do not administer.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.05pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-27.15pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.05pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-27.15pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>6.      Pemetrexed solutions are
for single use only. Any unused medicinal product or waste material must be
disposed of in accordance with local requirements.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB>Preparation and administration precautions</span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>As with other potentially toxic anticancer agents, care should be
exercised in the handling and preparation of pemetrexed infusion solutions. The
use of gloves is recommended. If a pemetrexed solution contacts the skin, wash
the skin immediately and thoroughly with soap and water. If pemetrexed
solutions contact the mucous membranes, flush thoroughly with water. Pemetrexed
is not a vesicant. There is not a specific antidote for extravasation of
pemetrexed. There have been few reported cases of pemetrexed extravasation,
which were not assessed as serious by the investigator. Extravasation should be
managed by local standard practice as with other non-vesicants.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>7.       MARKETING AUTHORISATION HOLDER</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Actavis Group
PTC ehf.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Reykjavíkurvegi
76&#8209;78</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>220
Hafnarfjörður</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Iceland</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>8.       MARKETING AUTHORISATION NUMBER(S) </span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EU/1/15/1063/001</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EU/1/15/1063/002</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EU/1/15/1063/003</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EU/1/15/1063/004</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>9.       DATE OF FIRST AUTHORISATION/RENEWAL OF THE
AUTHORISATION</span></b></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Date of first
authorisation: 18 January 2016</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Date of latest
renewal:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>10.     DATE OF REVISION OF THE TEXT</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>Detailed
information on this medicinal product is available on the website of the
European Medicines Agency <a href="http://www.ema.europa.eu">http://www.ema.europa.eu</a></span><span
lang=EN-GB style='color:blue'>.</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal align=center style='margin-top:14.0pt;margin-right:6.0pt;
margin-bottom:11.0pt;margin-left:6.35pt;text-align:center;text-autospace:none'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:5.95pt;margin-bottom:
0in;margin-left:6.25pt;margin-bottom:.0001pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:5.95pt;margin-bottom:
0in;margin-left:6.25pt;margin-bottom:.0001pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:5.95pt;margin-bottom:
0in;margin-left:6.25pt;margin-bottom:.0001pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:5.95pt;margin-bottom:
0in;margin-left:6.25pt;margin-bottom:.0001pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:5.95pt;margin-bottom:
0in;margin-left:6.25pt;margin-bottom:.0001pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:5.95pt;margin-bottom:
0in;margin-left:6.25pt;margin-bottom:.0001pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:5.95pt;margin-bottom:
0in;margin-left:6.25pt;margin-bottom:.0001pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:5.95pt;margin-bottom:
0in;margin-left:6.25pt;margin-bottom:.0001pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:5.95pt;margin-bottom:
0in;margin-left:6.25pt;margin-bottom:.0001pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:5.95pt;margin-bottom:
0in;margin-left:6.25pt;margin-bottom:.0001pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:5.95pt;margin-bottom:
0in;margin-left:6.25pt;margin-bottom:.0001pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:5.95pt;margin-bottom:
0in;margin-left:6.25pt;margin-bottom:.0001pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:5.95pt;margin-bottom:
0in;margin-left:6.25pt;margin-bottom:.0001pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:5.95pt;margin-bottom:
0in;margin-left:6.25pt;margin-bottom:.0001pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:5.95pt;margin-bottom:
0in;margin-left:6.25pt;margin-bottom:.0001pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:5.95pt;margin-bottom:
0in;margin-left:6.25pt;margin-bottom:.0001pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:5.95pt;margin-bottom:
0in;margin-left:6.25pt;margin-bottom:.0001pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:5.95pt;margin-bottom:
0in;margin-left:6.25pt;margin-bottom:.0001pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:5.95pt;margin-bottom:
0in;margin-left:6.25pt;margin-bottom:.0001pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:5.95pt;margin-bottom:
0in;margin-left:6.25pt;margin-bottom:.0001pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:5.95pt;margin-bottom:
0in;margin-left:6.25pt;margin-bottom:.0001pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:5.95pt;margin-bottom:
0in;margin-left:6.25pt;margin-bottom:.0001pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='margin-top:0in;margin-right:5.95pt;
margin-bottom:0in;margin-left:6.35pt;margin-bottom:.0001pt;text-align:center;
line-height:normal;text-autospace:none'><b><span lang=EN-GB style='color:black'>ANNEX
II</span></b></p>

<p class=MsoNormal align=center style='margin-right:5.95pt;text-align:center;
line-height:normal;text-autospace:none'><b><span lang=EN-GB style='color:black'>&nbsp;</span></b></p>

<p class=MsoListParagraph style='margin-top:0in;margin-right:5.95pt;margin-bottom:
0in;margin-left:0in;margin-bottom:.0001pt;text-indent:0in;line-height:normal;
text-autospace:none'><b><span lang=EN-GB style='color:black'>A.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></b><b><span lang=EN-GB style='color:black'>MANUFACTURER(S)
RESPONSIBLE FOR BATCH RELEASE</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:5.95pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:5.95pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><b><span lang=EN-GB style='color:black'>B.      CONDITIONS
OR RESTRICTIONS REGARDING SUPPLY AND USE</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:5.95pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:5.95pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><b><span lang=EN-GB style='color:black'>C.      OTHER
CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:5.95pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:5.95pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><b><span lang=EN-GB style='color:black'>D.      CONDITIONS
OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL
PRODUCT</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:5.95pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'><br clear=all style='page-break-before:always'>
</span></b>

<p class=TitleB style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.1pt;line-height:normal;page-break-after:auto'><span lang=EN-GB>A.      MANUFACTURER(S)
RESPONSIBLE FOR BATCH RELEASE</span></p>

<p class=MsoNormal style='margin-right:6.0pt;line-height:normal;text-autospace:
none'><u><span lang=EN-GB style='color:black'><span style='text-decoration:
 none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='margin-right:6.0pt;line-height:normal;text-autospace:
none'><u><span lang=EN-GB style='color:black'>Name and address of the
manufacturers responsible for batch release</span></u></p>

<p class=MsoNormal style='margin-right:6.0pt;line-height:normal;text-autospace:
none'><u><span lang=EN-GB style='color:black'><span style='text-decoration:
 none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal'>PLIVA CROATIA Ltd.</p>

<p class=MsoNormal style='line-height:normal'>10000 Zagreb</p>

<p class=MsoNormal style='line-height:normal'>Prilaz baruna Filipovi&#263;a 25</p>

<p class=MsoNormal style='line-height:normal'>Croatia</p>

<p class=MsoNormal style='margin-right:6.0pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:6.0pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='color:black'>Actavis Italy S.p.A.</span></p>

<p class=MsoNormal style='margin-right:6.0pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='color:black'>Via Pasteur, 10</span></p>

<p class=MsoNormal style='margin-right:6.0pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='color:black'>20014</span></p>

<p class=MsoNormal style='margin-right:6.0pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='color:black'>Nerviano, Milan</span></p>

<p class=MsoNormal style='margin-right:6.0pt;line-height:normal;text-autospace:
none'><span style='color:black'>Italy</span></p>

<p class=MsoNormal style='margin-right:6.0pt;line-height:normal;text-autospace:
none'><span style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:6.0pt;line-height:normal;text-autospace:
none'><span style='color:black'>S.C. SINDAN-PHARMA S.R.L.</span></p>

<p class=MsoNormal style='margin-right:6.0pt;line-height:normal;text-autospace:
none'><span style='color:black'>11 Ion Mihalache Blvd.</span></p>

<p class=MsoNormal style='margin-right:6.0pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='color:black'>RO-011171 Bucharest</span></p>

<p class=MsoNormal style='margin-right:6.0pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='color:black'>Romania</span></p>

<p class=MsoNormal style='margin-right:6.0pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:6.0pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='color:black'>The printed package leaflet of the
medicinal product must state the name and address of the manufacturer
responsible for the release of the concerned batch.</span></p>

<p class=MsoNormal style='margin-right:6.0pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:6.0pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=TitleB style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.1pt;line-height:normal;page-break-after:auto'><span lang=EN-GB>B.      CONDITIONS
OR RESTRICTIONS REGARDING SUPPLY AND USE</span></p>

<p class=MsoNormal style='margin-right:6.0pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:6.0pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='color:black'>Medicinal product subject to
restricted medical prescription (see Annex I: Summary of Product
Characteristics, section 4.2).</span></p>

<p class=MsoNormal style='margin-right:6.0pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:6.0pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=TitleB style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.1pt;line-height:normal;page-break-after:auto'><span lang=EN-GB>C.      OTHER
CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION</span></p>

<p class=MsoNormal style='margin-right:6.0pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:0in;text-indent:0in;line-height:normal;
text-autospace:none'><span lang=EN-GB style='font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB style='color:black'>Periodic safety update
reports (PSURs)</span></b></p>

<p class=MsoNormal style='margin-right:6.0pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:6.0pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='color:black'>The requirements for submission of PSURs
for this medicinal product are set out in the list of Union reference dates
(EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any
subsequent updates published on the European medicines web-portal.</span></p>

<p class=MsoNormal style='margin-right:6.0pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:6.0pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=TitleB style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.1pt;line-height:normal;page-break-after:auto'><span lang=EN-GB>D.      CONDITIONS
OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL
PRODUCT</span></p>

<p class=MsoNormal style='margin-right:6.0pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:0in;text-indent:0in;line-height:normal;
text-autospace:none'><span lang=EN-GB style='font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB style='color:black'>Risk management plan
(RMP)</span></b></p>

<p class=MsoNormal style='margin-right:6.0pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:6.0pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='color:black'>The marketing authorisation holder (MAH)
shall perform the required pharmacovigilance activities and interventions
detailed in the agreed RMP presented in Module 1.8.2 of the marketing authorisation
and any agreed subsequent updates of the RMP.</span></p>

<p class=MsoNormal style='margin-right:6.0pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='color:black'>An updated RMP should be submitted:</span></p>

<p class=MsoNormal style='margin-left:0in;text-indent:0in;line-height:normal;
text-autospace:none'><span lang=EN-GB style='font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>At the request of the
European Medicines Agency;</span></p>

<p class=MsoNormal style='margin-left:40.5pt;text-indent:-40.5pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol;
color:black'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>Whenever the risk management
system is modified, especially as the result of new information being received
that may lead to a significant change to the benefit/risk profile or as the
result of an important (pharmacovigilance or risk minimisation) milestone being
reached.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:0in;text-indent:0in;line-height:normal;
page-break-after:avoid;text-autospace:none'><span lang=EN-GB style='font-family:
Symbol;color:black'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB style='color:black'>Additional risk
minimisation measures </span></b></p>

<p class=MsoNormal style='margin-right:6.0pt;line-height:normal;page-break-after:
avoid;text-autospace:none'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:6.0pt;line-height:normal;page-break-after:
avoid;text-autospace:none'><span lang=EN-GB style='color:black'>Not applicable.</span></p>

<p class=MsoNormal style='margin-right:6.0pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:0in;text-indent:0in;line-height:normal;
text-autospace:none'><span lang=EN-GB style='font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB style='color:black'>Obligation to conduct
post-authorisation measures </span></b></p>

<p class=MsoNormal style='margin-right:6.0pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:6.0pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='color:black'>Not applicable.</span></p>

<p class=MsoNormal style='margin-right:6.0pt;line-height:14.0pt;text-autospace:
none'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>ANNEX
III</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>LABELLING
AND PACKAGE LEAFLET</span></b></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=TitleA><span lang=EN-GB>A. LABELLING</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'><br clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>PARTICULARS TO APPEAR ON THE OUTER PACKAGING</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>CARTON</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>1.       NAME OF THE
MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Armisarte 25&nbsp;mg/ml concentrate for solution for infusion </span></p>

<p class=MsoNormal style='margin-right:145.65pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>pemetrexed</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>2.       STATEMENT OF
ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Each ml of
concentrate contains 25&nbsp;mg pemetrexed (as pemetrexed diacid).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Each vial of 4&nbsp;ml
contains 100&nbsp;mg pemetrexed (as pemetrexed diacid).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:lightgrey'>Each vial of 20&nbsp;ml contains 500&nbsp;mg
pemetrexed (as pemetrexed diacid).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:lightgrey'>Each vial of 34&nbsp;ml contains 850&nbsp;mg
pemetrexed (as pemetrexed diacid).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:lightgrey'>Each vial of 40&nbsp;ml contains 1000&nbsp;mg pemetrexed
(as pemetrexed diacid).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>3.       LIST OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Excipients: trometamol</span><span
lang=EN-GB>, citric acid, methionine and water for injections.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>4.       PHARMACEUTICAL
FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-1.0pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='background:lightgrey'>Concentrate for solution
for infusion.</span></p>

<p class=MsoNormal style='margin-right:-1.0pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>4&nbsp;ml vial</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:lightgrey'>20&nbsp;ml vial</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:lightgrey'>34&nbsp;ml vial</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:lightgrey'>40&nbsp;ml vial</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>5.       METHOD AND
ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>For intravenous
use after dilution.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Must only be
diluted in 5%&nbsp;glucose solution.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Read the package
leaflet before use.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-1.0pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>For single use only.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>6.       SPECIAL WARNING
THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF
CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Keep out of the sight
and reach of children.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>7.       OTHER SPECIAL
WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Cytotoxic</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>8.       EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-1.0pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal style='margin-right:-1.0pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>9.       SPECIAL STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal'><span
lang=EN-GB>Store and transport refrigerated.</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal'><span
lang=EN-GB>Do not freeze.</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal'><span
lang=EN-GB>Keep the vial in the outer carton to protect from light</span><span
lang=EN-GB>.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>10.     SPECIAL PRECAUTIONS
FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH
MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='margin-right:-1.0pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>11.     NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Actavis Group
PTC ehf.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>220 Hafnarfjörður</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Iceland</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>12.     MARKETING AUTHORISATION NUMBER(S) </span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EU/1/15/1063/001
<i><span style='background:lightgrey'>4 ml vial</span></i></span></p>

<p class=MsoNormal style='line-height:normal'><span lang=DE style='background:
lightgrey'>EU/1/15/1063/002 <i>20 ml vial</i></span></p>

<p class=MsoNormal style='line-height:normal'><span lang=DE style='background:
lightgrey'>EU/1/15/1063/004 <i>34 ml vial</i></span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:lightgrey'>EU/1/15/1063/003 <i>40 ml vial</i></span></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>13.     BATCH NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>14.     GENERAL CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>15.     INSTRUCTIONS ON USE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>16.     INFORMATION IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black;background:#CCCCCC'>Justification
for not including Braille accepted.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:#CCCCCC'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='page-break-after:avoid;border:none;padding:0in'><b><span
lang=EN-GB>17.     UNIQUE IDENTIFIER  2D BARCODE</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='background:lightgrey'>2D barcode carrying the unique identifier
included.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>18.     UNIQUE
IDENTIFIER - HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>PC</span></p>

<p class=MsoNormal><span lang=EN-GB>SN</span></p>

<p class=MsoCommentText><span lang=EN-GB style='font-size:11.0pt'>NN</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS</span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>VIAL LABEL</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:3.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>1.       NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF
ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Armisarte 25&nbsp;mg/ml sterile concentrate</span></p>

<p class=MsoNormal style='margin-right:145.65pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>pemetrexed</span></p>

<p class=MsoNormal style='margin-right:-1.0pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>IV</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>2.       METHOD OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>3.       EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>4.       BATCH NUMBER</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>Lot</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:0in 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>5.       CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>100 mg/4 ml</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>6.       OTHER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>Cytotoxic</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS</span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>VIAL LABEL </span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:3.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>1.       NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF
ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Armisarte 25 mg/ml concentrate for solution for infusion </span></p>

<p class=MsoNormal style='margin-right:145.65pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>pemetrexed</span></p>

<p class=MsoNormal style='margin-right:-1.0pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>IV</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>2.       METHOD OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>3.       EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>4.       BATCH NUMBER</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>Lot</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:0in 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>5.       CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=DE>500 mg/20 ml</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=DE style='background:lightgrey'>850 mg/34 ml</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=DE style='background:
lightgrey'>1000 mg/40 ml</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=DE>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=DE>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>6.       OTHER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>Cytotoxic</span></p>

<b><u><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></u></b>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=TitleA><span lang=EN-GB>B. PACKAGE LEAFLET</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal align=center style='text-align:center;line-height:normal;
text-autospace:none'><b><span lang=EN-GB>Package leaflet: Information for the
user</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal;
text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal;
text-autospace:none'><b><span lang=EN-GB>Armisarte 25&nbsp;mg/ml concentrate
for solution for infusion</span></b></p>

<p class=MsoNormal align=center style='margin-right:.45pt;text-align:center;
line-height:normal;text-autospace:none'><span lang=EN-GB>pemetrexed</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal;
text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>Read all of this leaflet carefully before you start receiving this
medicine because it contains important information for you.</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>-        </span></b><span lang=EN-GB>Keep this leaflet. You may need
to read it again.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>-        If you have any further questions, ask your doctor or pharmacist.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>-        If you get any side
effects, talk to your doctor or nurse or pharmacist. This includes any possible
side effects not listed in this leaflet. See section&nbsp;4.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:47.0pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>What is in this leaflet</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>1.       What Armisarte is and what it is used for</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>2.       What you need to know before you use Armisarte</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>3.       How to use Armisarte</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>4.       Possible side effects</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>5.       How to store Armisarte</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>6.       Contents of the pack and other information</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>1.       What Armisarte is and what it is used for</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Armisarte is a medicine used in the treatment of cancer. It contains
the active substance pemetrexed. Pemetrexed belongs to a group of medicines
known as folic acid analogues and disrupts processes that are essential for
cells to divide.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Armisarte is given in combination with cisplatin, another
anti-cancer medicine, as treatment for malignant pleural mesothelioma, a form
of cancer that affects the lining of the lung, to patients who have not
received prior chemotherapy.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Armisarte is also given in combination with cisplatin for the
initial treatment of patients with advanced stage of lung cancer.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Armisarte can be prescribed to you if you have lung cancer at an
advanced stage if your disease has responded to treatment or it remains largely
unchanged after initial chemotherapy.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Armisarte is also a treatment for patients with advanced stage of
lung cancer whose disease has progressed after other initial chemotherapy has
been used.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>2.       What you need to know before you use Armisarte </span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>Do not use Armisarte</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>-        if you are allergic to
pemetrexed or any of the other ingredients of this medicine (listed in
section&nbsp;6).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>-        if you are
breast-feeding; you must discontinue breast-feeding during treatment with Armisarte.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>-        if you have recently received or are about to receive a
vaccine against yellow fever.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>Warnings and precautions</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB>Talk to your doctor or hospital pharmacist before receiving Armisarte.</span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>If you currently have or have previously had problems with your
kidneys, talk to your doctor or hospital pharmacist as you may not be able to
receive Armisarte.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Before each infusion you will have samples of your blood taken to
evaluate if you have sufficient kidney and liver function and to check that you
have enough blood cells to receive Armisarte. Your doctor may decide to change
the dose or delay treating you depending on your general condition and if your
blood cell counts are too low. If you are also receiving cisplatin, your doctor
will make sure that you are properly hydrated and receive appropriate treatment
before and after receiving cisplatin to prevent vomiting.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>If you have had or are going to have radiation therapy, please tell
your doctor, as there may be an early or late radiation reaction with Armisarte.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>If you have been recently vaccinated, please tell your doctor, as
this can possibly cause bad effects with Armisarte.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>If you have heart disease or a history of heart disease, please tell
your doctor.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>If you have an accumulation of fluid around your lungs, your doctor
may decide to remove the fluid before giving you Armisarte.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>Children and adolescents</span></b></p>

<p class=MsoNormal><span lang=EN-GB>This medicine should not be used in
children or adolescents, since there is no experience with this medicine in
children and adolescents under 18&nbsp;years of age.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>Other medicines and Armisarte</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Tell your doctor or pharmacist if you are taking, have recently
taken or might take any other medicines, including </span><span lang=EN-GB>medicine
for pain or inflammation (swelling), such as medicines called nonsteroidal
anti-inflammatory medicinal products (NSAIDs), including medicines purchased
without a doctors prescription (such as ibuprofen). There are many sorts of
NSAIDs with different durations of activity. Based on the planned date of your
infusion of Armisarte and/or on the status of your kidney function, your doctor
needs to advise you on which medicines you can take and when you can take them.
If you are unsure, ask your doctor or pharmacist if any of your medicines are NSAIDs.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Like other chemotherapy medicines Armisarte is not recommended with
live attenuated vaccines. Inactive vaccines should be used where possible.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>Pregnancy</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>If you are pregnant, think you may be pregnant or are planning to
have a baby, <b>tell your doctor</b>. The use of Armisarte should be avoided
during pregnancy. Your doctor will discuss with you the potential risk of
taking Armisarte during pregnancy. Women must use effective contraception
during treatment with Armisarte.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>Breast-feeding</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>If you are breast-feeding, tell your doctor.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Breast-feeding must be discontinued during treatment with Armisarte.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>Fertility</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Men are advised not to father a child during and up to 6&nbsp;months
following treatment with Armisarte and should therefore use effective
contraception during treatment with Armisarte and for up to 6&nbsp;months
afterwards. If you would like to father a child during the treatment or in the
6&nbsp;months following receipt of treatment, seek advice from your doctor or
pharmacist. You may want to seek counselling on sperm storage before starting
your therapy.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>Driving and using machines</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Armisarte</span><span lang=EN-GB> may make you feel tired. Be
careful when driving a car or using machines.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>3.       How to use Armisarte</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Armisarte</span><span lang=EN-GB> 25&nbsp;mg/ml concentrate for
solution for infusion will always be given to you by a healthcare professional.</span><span
lang=EN-GB> The dose of Armisarte is 500&nbsp;milligrams for every square metre
of your bodys surface area. Your height and weight are measured to work out
the surface area of your body. Your doctor will use this body surface area to
work out the right dose for you. This dose may be adjusted, or treatment may be
delayed depending on your blood cell counts and on your general condition. A
hospital pharmacist, nurse or doctor will have mixed the Armisarte concentrate
with 5%&nbsp;glucose solution for injection before it is given to you.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>You will always receive Armisarte by infusion into one of your
veins. The infusion will last approximately 10&nbsp;minutes.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>When using Armisarte in combination with cisplatin:</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>The doctor or hospital pharmacist will work out the dose you need
based on your height and weight. Cisplatin is also given by infusion into one
of your veins, and is given approximately 30&nbsp;minutes after the infusion of
Armisarte has finished. The infusion of cisplatin will last approximately
2&nbsp;hours.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>You should usually receive your infusion once every 3&nbsp;weeks. </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Additional medicines: </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Corticosteriods: your doctor will prescribe you steroid tablets
(equivalent to 4&nbsp;milligram of dexamethasone twice a day) that you will
need to take on the day before, on the day of, and the day after Armisarte
treatment. This medicine is given to you to reduce the frequency and severity
of skin reactions that you may experience during your anticancer treatment.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Vitamin supplementation: your doctor will prescribe you oral folic
acid (vitamin) or a multivitamin containing folic acid (350 to
1000&nbsp;micrograms) that you must take once a day while you are receiving Armisarte.
You must take at least 5&nbsp;doses during the seven days before the first dose
of Armisarte. You must continue taking the folic acid for 21&nbsp;days after
the last dose of Armisarte. You will also receive an injection of vitamin B<sub>12</sub>
(1000&nbsp;micrograms) in the week before administration of Armisarte and then
approximately every 9&nbsp;weeks (corresponding to 3&nbsp;courses of Armisarte
treatment). Vitamin B<sub>12</sub> and folic acid are given to you to reduce
the possible toxic effects of the anticancer treatment.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Your condition will be closely monitored during treatment. This
routinely involves blood tests, including checks on your liver and kidney
function. Your dose may be changed or treatment delayed depending on results
from these tests.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>If you have any further questions on the use of this medicine, ask
your doctor or pharmacist.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>4.       Possible side effects</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Like all medicines, this medicine can cause side effects, although
not everybody gets them. </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>You must contact your doctor
immediately if you notice any of the following:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Fever or infection (common): if you have a
temperature of 38&nbsp;°C or greater, sweating or other signs of
infection(since you might have less white blood cells than normal which is very
common). Infection (sepsis) may be severe and could lead to death</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you start feeling chest pain (common) or
having a fast heart rate (uncommon)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you have pain, redness, swelling or sores in
your mouth (very common)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='color:black'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Allergic reaction: if you develop skin rash
(very common) / burning or prickling sensation (common), or fever (common).
Rarely, skin reactions may be severe and could lead to death<span
style='color:blue'>. </span><span style='color:black'>Contact your doctor if
you get a severe rash</span><span style='color:blue'>, </span><span
style='color:black'>or itching</span><span style='color:blue'>, </span><span
style='color:black'>or blistering (Stevens-Johnson Syndrome or Toxic epidermal
necrolysis)</span></span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='color:black'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>If you experience tiredness,
feeling faint, becoming easily breathless or if you look pale (since you might
have less haemoglobin than normal which is very common)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='color:black'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>If you experience bleeding
from the gums, nose or mouth or any bleeding that would not stop, reddish or
pinkish urine, unexpected bruising (since you might have less platelets than
normal which is very common)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='color:black'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>If you experience sudden
breathlessness, intense chest pain or cough with bloody sputum (uncommon)(may
indicate a blood clot in the blood vessels of the lungs)</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal'><span
lang=EN-GB>Other side effects with Armisarte may include:</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><a name="_Hlk29993282"><i><span lang=EN-GB>Very common </span></i></a><i><span
lang=EN-GB>(may affect more than 1 in 10 people)</span></i></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Infection</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Pharyngitis (a sore throat)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Low number of neutrophil granulocytes (a type of
white blood cell)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Low white blood cells</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Low haemoglobin level </span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Pain, redness, swelling or sores in your mouth</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Loss of appetite</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Vomiting</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Diarrhoea</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Nausea</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Skin rash</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Flaking skin</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Abnormal blood tests showing reduced functionality
of kidneys</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Fatigue (tiredness)</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Common (may affect up to 1 in 10 people)</span></i></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Blood infection</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Fever with low number of neutrophil granulocytes
(a type of white blood cell)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Low platelet count</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Allergic reaction</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Loss of body fluids</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Taste change</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Damage to the motor nerves which may cause
muscle weakness and atrophy (wasting) primary in the arms and legs)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Damage to the sensory nerves that may cause lost
of sensation, burning pain and unsteady gait</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Dizziness</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Inflammation or swelling of the conjunctiva (the
membrane that lines the eyelids and covers the white of the eye</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Dry eye</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Watery eyes</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Dryness of the conjunctiva (the membrane that
lines the eyelids and covers the white of the eye) and cornea (the clear layer
in front of the iris and pupil.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Swelling of the eyelids</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Eye disorder with dryness, tearing, irritation,
and/or pain</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Cardiac Failure (Condition that affects the
pumping power of your heart muscles)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Irregular heart rhythm</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Indigestion</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Constipation</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Abdominal pain</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Liver: increases in the chemicals in the blood
made by the liver</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Increased skin pigmentation</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Itchy skin</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Rash on the body where each mark resembles a
bullseye</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Hair loss</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Hives</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Kidney stop working</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Reduced functionality of kidney</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Fever</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Pain</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Excess fluid in body tissue, causing swelling</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Chest pain</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Inflammation and ulceration of the mucous
membranes lining the digestive tract</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Uncommon (may affect up to 1 in 100
people)</span></i></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Reduction in the number of red,white blood cells
and platelets</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Stroke</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Type of stroke when an artery to the brain is
blocked</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Bleeding inside the skull</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Angina (Chest pain caused by reduced blood flow
to the heart)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Heart attack</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Narrowing or blockage of the coronary arteries</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Abnormal heart rhythm</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Deficient blood distribution to the limbs</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Blockage in one of the pulmonary arteries in
your lungs</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Inflammation and scarring of the lining of the
lungs with breathing problems</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Passage of bright red blood from the anus</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Bleeding in the gastrointestinal tract</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Ruptured bowel</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Inflammation of the lining of the oesophagus</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Inflammation of the lining of the large bowel,
which may be accompanied by intestinal or rectal bleeding (seen only in
combination with cisplatin)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Inflammation, edema, erythema, and erosion of
the mucosal surface of the esophagus caused by radiation therapy</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Inflammation of the lung caused by radiation
therapy</span></p>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal><i><span lang=EN-GB>Rare (may affect up to 1 in 1,000
people)</span></i></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Destruction of red blood cells</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Anaphylactic shock (severe allergic reaction)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Inflammatory condition of the liver</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Redness of the skin</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Skin rash that develops throughout a previously
irradiated area</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Very rare (affect up to 1 of 10 000
people)</span></i></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Infections of skin and soft tissues</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Stevens-Johnson syndrome (a type of severe skin
and mucous membranes reaction that may be life threatening)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Toxic epidermal necrolysis (a type of severe
skin reaction that may be life threatening)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Autoimmune disorder that results in skin rashes
and blistering on the legs, arms, and abdomen</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Inflammation of the skin characterized by the
presence of bullae which are filled with fluid</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Skin fragility, blisters and erosions and skin
scarring</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Redness, pain and swelling mainly of the lower
limbs</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Inflammation of the skin and fat beneath the
skin (pseudocellulitis)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Inflammation of the skin (dermatitis)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Skin to become inflamed, itchy, red, cracked,
and rough</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Intensely itchy spots</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Not known: frequency cannot be estimated
from the available data</span></i></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Form of diabetes primarily due to pathology of
the kidney</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Disorder of the kidneys involving the death of
tubular epithelial cells that form the renal tubules</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>You might have any of these symptoms and/or conditions. You must
tell your doctor as soon as possible when you start experiencing any of these
side effects.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Reporting of
side effects</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>If you get any
side effects, talk to your doctor or nurse.</span><span lang=EN-GB
style='color:red'> </span><span lang=EN-GB>This includes any possible side
effects not listed in this leaflet. You can also report side effects directly
via <span style='background:lightgrey'>the national reporting system listed in </span></span><span
lang=EN-GB><a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><span
style='background:lightgrey'>Appendix V</span></a></span><span lang=EN-GB>. By
reporting side effects you can help provide more information on the safety of
this medicine.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB style='color:black'>5.       How to store Armisarte</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB style='color:black'>Keep this medicine out of the sight and reach of
children.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB style='color:black'>Do not use this medicine after the expiry date </span><span
lang=EN-GB>which is stated on the label and carton after EXP. The expiry date
refers to the last day of that month.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal'><span
lang=EN-GB>Store and transport refrigerated (2&nbsp;°C-8&nbsp;°C).</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal'><span
lang=EN-GB>Do not freeze.</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Keep the vial in
the outer carton in order to protect from light.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;text-autospace:
none'><i><span lang=EN-GB style='color:black'>Infusion Solution:</span></i><span
lang=EN-GB style='color:black'> </span><span lang=EN-GB>Chemical and physical
in-use stability of infusion solution of pemetrexed was demonstrated for 24&nbsp;hours
at room temperature and 7&nbsp;days at refrigerated temperature. From a
microbiological point of view, the product should be used immediately. If not
used immediately, in-use storage times and conditions prior to use are the
responsibility of the user and would not be longer than 24&nbsp;hours at 2&nbsp;°C-8&nbsp;°C</span><span
lang=EN-GB>, unless dilution has taken place in controlled and validated
aseptic conditions</span><span lang=EN-GB>.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Armisarte should not been used if there are any signs of particles.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB style='color:black'>This medicine is for single use only; any unused
solution must be disposed of in accordance with local requirements.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB style='color:black'>6.       Contents of the pack and other
information</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>What </span></b><b><span lang=EN-GB>Armisarte contains</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB style='color:black'>The active substance is pemetrexed. Each</span><span
lang=EN-GB> ml of concentrate contains 25&nbsp;mg </span><span lang=EN-GB
style='color:black'>pemetrexed (as pemetrexed diacid).</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Each vial of 4&nbsp;ml
concentrate contains 100&nbsp;mg pemetrexed (as pemetrexed diacid)</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Each vial of 20&nbsp;ml
concentrate contains 500&nbsp;mg pemetrexed (as pemetrexed diacid)</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Each vial of
34&nbsp;ml concentrate contains 850&nbsp;mg pemetrexed (as pemetrexed diacid)</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Each vial of 40&nbsp;ml
concentrate contains 1000&nbsp;mg pemetrexed (as pemetrexed diacid)</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>The other ingredients are t</span><span lang=EN-GB>rometamol
(for pH adjustment), citric acid, methionine and water for injection.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB style='color:black'>What Armisarte looks like and contents of the
pack</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>Armisarte </span><span lang=EN-GB>concentrate for solution
for infusion (sterile concentrate) <span style='color:black'>is a</span> clear,
colourless to slightly yellowish or yellow-greenish solution.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Armisarte is
provided in a colourless glass vial with rubber stopper and an aluminium cap
with polypropylene disk. Vials may or may not be sheathed in a protective
sleeve.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB style='color:black'>Each pack of Armisarte contains one vial.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Pack sizes</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>1 x 4&nbsp;ml
vial (100 mg/4 ml)</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>1 x 20&nbsp;ml
vial (500 mg/20 ml)</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>1 x 34&nbsp;ml
vial (850 mg/34 ml)</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>1 x 40&nbsp;ml
vial (1000 mg/40 ml)</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Not all pack
sizes may be marketed.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-1.0pt;line-height:normal;text-autospace:
none'><b><span lang=EN-GB style='color:black'>Marketing Authorisation Holder</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Actavis Group
PTC ehf.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Reykjavíkurvegi
76&#8209;78</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>220
Hafnarfjörður</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Iceland</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal'><b><span
lang=EN-GB style='color:black'>Manufacturer</span></b></p>

<p class=MsoNormal>PLIVA CROATIA Ltd.</p>

<p class=MsoNormal>10000 Zagreb</p>

<p class=MsoNormal>Prilaz baruna Filipovi&#263;a 25</p>

<p class=MsoNormal>Croatia</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:lightgrey'>Actavis Italy S.p.A.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:lightgrey'>Viale Pasteur 10</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:lightgrey'>20014 Nerviano (Milan)</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:lightgrey'>Italy</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:lightgrey'>S.C. Sindan-Pharma S.R.L.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:lightgrey'>11 Ion Mihalache Blvd.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:lightgrey'>011171 Bucharest</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:lightgrey'>Romania</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>For any information about this medicine, please contact the local
representative of the Marketing Authorisation Holder:</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=622
 style='margin-left:-.2pt;border-collapse:collapse'>
 <tr style='page-break-inside:avoid'>
  <td width=310 valign=top style='width:232.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-right:28.35pt;line-height:normal'><b><span
  lang=DE>België/Belgique/Belgien</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=FR>Teva Pharma
  Belgium N.V./S.A./AG</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=NL-BE>Tel/Tél: + 32
  (0)38 20 73 73</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-right:28.35pt;line-height:normal'><b><span
  lang=EN-GB>Lietuva</span></b></p>
  <p class=MsoNormal style='margin-right:28.35pt;line-height:normal'><span
  lang=EN-GB>UAB &quot;Sicor Biotech&quot;</span></p>
  <p class=MsoNormal style='margin-right:28.35pt;line-height:normal'><span
  lang=DA>Tel: +370 5 </span><span lang=EN-GB>266 0203</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=310 valign=top style='width:232.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-right:28.35pt;line-height:normal;text-autospace:
  none'><b><span lang=EN-GB>&#1041;&#1098;&#1083;&#1075;&#1072;&#1088;&#1080;&#1103;</span></b></p>
  <p class=MsoNormal style='margin-right:28.35pt;line-height:normal;text-autospace:
  none'><span lang=BG>&#1040;&#1082;&#1090;&#1072;&#1074;&#1080;&#1089;
  &#1045;&#1040;&#1044;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Te</span><span
  lang=RU>&#1083;.: +</span><span lang=BG>359 2 </span><span lang=EN-GB>489 95
  85</span></p>
  <p class=MsoNormal style='margin-right:28.35pt;line-height:normal'><b><span
  lang=DA>&nbsp;</span></b></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-right:28.35pt;line-height:normal'><b><span
  lang=DE>Luxembourg/Luxemburg</span></b></p>
  <p class=MsoNormal style='margin-right:28.35pt;line-height:normal'><span
  lang=FR>Teva Pharma Belgium N.V./S.A./AG</span></p>
  <p class=MsoNormal style='margin-right:28.35pt;line-height:normal'><span
  lang=NL-BE>Tel/Tél: + 32 (0)38 20 73 73</span></p>
  <p class=MsoNormal style='margin-right:28.35pt;line-height:normal'><b>&nbsp;</b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=310 valign=top style='width:232.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-right:28.35pt;line-height:normal'><b><span
  lang=EN-GB>&#268;eská republika</span></b></p>
  <p class=MsoNormal style='margin-right:28.35pt;line-height:normal'><span
  lang=EN-GB>Teva Pharmaceuticals CR, s.r.o.</span></p>
  <p class=MsoNormal style='line-height:normal'>Tel: <span lang=EN-GB>+</span><span
  lang=CS>420 251 007&nbsp;111</span></p>
  <p class=MsoNormal style='margin-right:28.35pt;line-height:normal'><b><span
  lang=DA>&nbsp;</span></b></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-right:28.35pt;line-height:normal'><b><span
  lang=DA>Magyarország</span></b></p>
  <p class=MsoNormal style='margin-right:28.35pt;line-height:normal'><span
  lang=DA>Teva Gyógyszergyár Zrt.</span></p>
  <p class=MsoNormal style='margin-right:28.35pt;line-height:normal'><span
  lang=DA>Tel.: +36 1 288 6400</span></p>
  <p class=MsoNormal style='margin-right:28.35pt;line-height:normal'><b><span
  lang=DA>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=310 valign=top style='width:232.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-right:28.35pt;line-height:normal'><b><span
  lang=DA>Danmark</span></b></p>
  <p class=MsoNormal style='margin-right:28.35pt;line-height:normal'><span
  lang=IS>Teva Denmark A/S</span></p>
  <p class=MsoNormal style='margin-right:28.35pt;line-height:normal'><span
  lang=IS>Tlf: +45 44 98 55 11</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=FR>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-right:28.35pt;line-height:normal'><b>Malta</b></p>
  <p class=MsoNormal style='margin-right:28.35pt;line-height:normal'><span
  lang=PT>Actavis Ltd.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=PT>Tel: +35621693533</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=PT>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:37.55pt'>
  <td width=310 valign=top style='width:232.4pt;padding:0in 5.4pt 0in 5.4pt;
  height:37.55pt'>
  <p class=MsoNormal style='margin-right:28.35pt;line-height:normal'><b><span
  lang=EN-GB>Deutschland</span></b></p>
  <p class=MsoNormal style='margin-right:28.35pt;line-height:normal'><span
  lang=EN-GB>ratiopharm GmbH</span></p>
  <p class=MsoNormal style='margin-right:28.35pt;line-height:normal'><span
  lang=EN-GB><a href="Tel:+49"><span style='color:windowtext'>Tel:&nbsp;+49</span></a></span><span
  lang=EN-GB>&nbsp;731&nbsp;402&nbsp;02</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=NO-BOK>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt;
  height:37.55pt'>
  <p class=MsoNormal style='margin-right:28.35pt;line-height:normal'><b><span
  lang=DA>Nederland</span></b></p>
  <p class=MsoNormal style='margin-right:28.35pt;line-height:normal'><span
  lang=DE>Teva Nederland B.V.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tel: +31 (0)
  800 0228 400</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=DE>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=310 valign=top style='width:232.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-right:28.35pt;line-height:normal'><b><span
  lang=EN-GB>Eesti</span></b></p>
  <p class=MsoNormal style='margin-right:28.35pt;line-height:normal'><span
  lang=EN-GB>UAB &quot;Sicor Biotech&quot; Eesti filiaal</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=FI>Tel: +372 </span><span
  lang=EN-GB>661 0801</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=PT>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-right:28.35pt;line-height:normal'><b><span
  lang=EN-GB>Norge</span></b></p>
  <p class=MsoNormal style='margin-right:28.35pt;line-height:normal'>Teva
  Norway AS</p>
  <p class=MsoNormal style='margin-right:28.35pt;line-height:normal'>Tlf: +47
  66 77 55 90</p>
  <p class=MsoNormal style='margin-right:28.35pt;line-height:normal'>&nbsp;</p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=310 valign=top style='width:232.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-right:28.35pt;line-height:normal'><b><span
  lang=EN-GB>&#917;&#955;&#955;&#940;&#948;&#945;</span></b></p>
  <p class=NormalParagraphStyle style='line-height:normal'><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif;color:windowtext'>Specifar
  ABEE</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EL style='border:
  none windowtext 1.0pt;padding:0in'>&#932;&#951;&#955;</span><span lang=EN-GB
  style='border:none windowtext 1.0pt;padding:0in'>: </span><span lang=EN-GB>+30
  210 5401500</span></p>
  <p class=MsoNormal style='margin-right:28.35pt;line-height:normal'><span
  lang=DE>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-right:28.35pt;line-height:normal'><b><span
  lang=DE>Österreich</span></b></p>
  <p class=MsoNormal style='margin-right:28.35pt;line-height:normal'><span
  lang=DE>ratiopharm Arzneimittel Vertriebs-GmbH</span></p>
  <p class=MsoNormal style='margin-right:28.35pt;line-height:normal'><span
  lang=DE>Tel: +43(0)1 97007 0</span></p>
  <p class=MsoNormal style='margin-right:28.35pt;line-height:normal'><span
  lang=NO-BOK>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=310 valign=top style='width:232.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-right:28.35pt;line-height:normal'><b><span
  lang=DE>España</span></b></p>
  <p class=MsoNormal style='margin-right:28.35pt;line-height:normal'><span
  lang=DE>Teva Pharma, S.L.U.</span></p>
  <p class=MsoNormal style='margin-right:28.35pt;line-height:normal'><span
  lang=EN-GB>Tél:&nbsp;+(34)&nbsp;91&nbsp;387&nbsp;32&nbsp;80 </span></p>
  <p class=MsoNormal style='margin-right:28.35pt;line-height:normal'><b><span
  lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-right:28.35pt;line-height:normal'><b><span
  lang=EN-GB>Polska</span></b></p>
  <p class=MsoNormal style='line-height:normal'>Teva Pharmaceuticals Polska Sp.
  z o.o.</p>
  <p class=MsoNormal style='line-height:normal'><span lang=PL>Tel: +48 22 345
  93 00</span></p>
  <p class=MsoNormal style='margin-right:28.35pt;line-height:normal'><b><span
  lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=310 valign=top style='width:232.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-right:28.35pt;line-height:normal'><b><span
  lang=EN-GB>France</span></b></p>
  <p class=MsoNormal style='margin-right:28.35pt;line-height:normal'><span
  lang=EN-GB>Teva Santé</span></p>
  <p class=MsoNormal style='margin-right:28.35pt;line-height:normal'><span
  lang=EN-GB>Tél:&nbsp;+(33)&nbsp;1&nbsp;55&nbsp;91&nbsp;78&nbsp;00</span></p>
  <p class=MsoNormal style='margin-right:28.35pt;line-height:normal'><b><span
  lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-right:28.35pt;line-height:normal'><b><span
  lang=PT>Portugal</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=PT>Teva Pharma -
  Produtos Farmacêuticos Lda</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=PT>Tel: +351 21 476
  75 50</span></p>
  <p class=MsoNormal style='margin-right:28.35pt;line-height:normal'><b><span
  lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=310 valign=top style='width:232.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Hrvatska</span></b></p>
  <p class=MsoNormal style='margin-right:28.35pt;line-height:normal'><span
  lang=EN-GB>Pliva Hrvatska d.o.o. </span></p>
  <p class=MsoNoSpacing><span lang=IS style='font-family:"Times New Roman",serif'>Tel:
  +385 1 37 20 000 </span></p>
  <p class=MsoNormal style='margin-right:28.35pt;line-height:normal'><b><span
  lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-right:28.35pt;line-height:normal'><b><span
  lang=EN-GB>România</span></b></p>
  <p class=MsoNormal style='margin-right:28.35pt;line-height:normal'><span
  lang=EN-GB>Teva Pharmaceuticals S.R.L</span></p>
  <p class=MsoNormal style='margin-right:28.35pt;line-height:normal'><span
  lang=DA>Tel: +</span><span lang=EN-GB>4021 230 65 24</span></p>
  <p class=MsoNormal style='margin-right:28.35pt;line-height:normal'><b><span
  lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=310 valign=top style='width:232.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-right:28.35pt;line-height:normal'><b><span
  lang=EN-GB>Ireland</span></b></p>
  <p class=MsoNormal style='margin-right:28.35pt;line-height:normal'><span
  lang=EN-GB>Actavis Ireland Limited</span></p>
  <p class=MsoNormal style='margin-right:28.35pt;line-height:normal'><span
  lang=EN-GB>Tel: +353 (0)21 4619040</span></p>
  <p class=MsoNormal style='margin-right:28.35pt;line-height:normal'><b><span
  lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-right:28.35pt;line-height:normal'><b><span
  lang=EN-GB>Slovenija</span></b></p>
  <p class=MsoNormal style='margin-right:-.05pt;line-height:normal'><span
  lang=EN-GB>Pliva Ljubljana d.o.o.</span></p>
  <p class=MsoNormal style='margin-right:-.05pt;line-height:normal'><span
  lang=EN-GB>Tel: +386 1 58 90 390</span></p>
  <p class=MsoNormal style='margin-right:28.35pt;line-height:normal'><b><span
  lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=310 valign=top style='width:232.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-right:28.35pt;line-height:normal'><b><span
  lang=DA>Ísland</span></b></p>
  <p class=MsoNormal style='margin-right:28.35pt;line-height:normal'><span
  lang=DA>Actavis Group PTC ehf.</span></p>
  <p class=MsoNormal style='margin-right:28.35pt;line-height:normal'><span
  lang=EN-GB>Sími: +354 550 3300</span></p>
  <p class=MsoNormal style='margin-right:28.35pt;line-height:normal'><b><span
  lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-right:28.35pt;line-height:normal'><b><span
  lang=DA>Slovenská republika</span></b></p>
  <p class=MsoNormal style='margin-right:28.35pt;line-height:normal'><span
  lang=SK>TEVA Pharmaceuticals Slovakia s.r.o</span></p>
  <p class=MsoNormal style='margin-right:28.35pt;line-height:normal'><span
  lang=DA>Tel: +421 2 </span><span lang=SK>57 26 79 11</span></p>
  <p class=MsoNormal style='margin-right:28.35pt;line-height:normal'><b><span
  lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=310 valign=top style='width:232.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-right:28.35pt;line-height:normal'><b><span
  lang=DA>Italia</span></b></p>
  <p class=MsoNormal style='margin-right:28.35pt;line-height:normal'><span
  lang=EN-GB>Teva Italia S.r.l.</span></p>
  <p class=MsoNormal style='margin-right:28.35pt;line-height:normal'><span
  lang=EN-GB>Tel:&nbsp;+(39)&nbsp;028917981</span></p>
  <p class=MsoNormal style='margin-right:28.35pt;line-height:normal'><b><span
  lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-right:28.35pt;line-height:normal'><b><span
  lang=DA>Suomi/Finland</span></b></p>
  <p class=MsoNormal style='margin-right:28.35pt;line-height:normal'><span
  lang=DA>ratiopharm Oy</span></p>
  <p class=MsoNormal style='margin-right:28.35pt;line-height:normal'><span
  lang=DA>Puh/Tel: +358&nbsp;(0) 20&nbsp;180 5900</span></p>
  <p class=MsoNormal style='margin-right:28.35pt;line-height:normal'><b><span
  lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=310 valign=top style='width:232.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-right:28.35pt;line-height:normal'><b><span
  lang=EN-GB>&#922;&#973;&#960;&#961;&#959;&#962;</span></b></p>
  <p class=MsoNormal style='margin-right:28.35pt;line-height:normal'><span
  lang=IS>Specifar ABEE </span></p>
  <p class=MsoNormal style='margin-right:28.35pt;line-height:normal'><span
  lang=EL>&#932;&#951;&#955;</span><span lang=IS>: +30 210 5401500</span></p>
  <p class=MsoNormal style='margin-right:28.35pt;line-height:normal'><span
  lang=EL>&#917;&#955;&#955;&#940;&#948;&#945;</span></p>
  <p class=MsoNormal style='margin-right:28.35pt;line-height:normal'>&nbsp;</p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-right:28.35pt;line-height:normal'><b><span
  lang=DE>Sverige</span></b></p>
  <p class=MsoNormal style='margin-right:28.35pt;line-height:normal'><span
  lang=DE>Teva Sweden AB</span></p>
  <p class=MsoNormal style='margin-right:28.35pt;line-height:normal'><span
  lang=DE>Tel: +46 42 12 11 00</span></p>
  <p class=MsoNormal style='margin-right:28.35pt;line-height:normal'><span
  lang=PT>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=310 valign=top style='width:232.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=SV>Latvija</span></b></p>
  <p class=MsoNormal style='line-height:normal'>UAB <span lang=EN-GB>&quot;Sicor
  Biotech&quot; fili&#257;le Latvij&#257;</span></p>
  <p class=MsoNormal style='line-height:normal'>Tel: +371 <span lang=EN-GB>673
  23&nbsp;666</span></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=FR>&nbsp;</span></b></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-right:28.35pt;line-height:normal'><b><span
  lang=EN-GB>United Kingdom</span></b></p>
  <p class=MsoNormal style='margin-right:28.35pt;line-height:normal'><span
  lang=EN-GB>Actavis UK Limited</span></p>
  <p class=MsoNormal style='margin-right:28.35pt;line-height:normal'><span
  lang=EN-GB>Tel: </span>+44 <span lang=EN-GB>1271 385257</span></p>
  <p class=MsoNormal style='margin-right:28.35pt;line-height:normal'><span
  lang=IT>&nbsp;</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal'><b><span
lang=EN-GB>This leaflet was last revised in</span></b></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>Other sources of information</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Detailed information on this medicine is available on the European
Medicines Agency web site: </span><span lang=EN-GB><a
href="http://www.ema.europa.eu">http://www.ema.europa.eu</a></span><span
lang=EN-GB style='color:blue'>/.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>---------------------------------------------------------------------------------------------------------------------------</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB style='color:black'>The following information is intended for
medical or healthcare professionals only:</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB style='color:black'>Instructions for use, handling and disposal</span></u></p>

<p class=MsoNormal style='margin-left:21.3pt;text-indent:-21.3pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='color:black'>1.       Use
aseptic techniques during dilution of pemetrexed for intravenous infusion
administration.</span></p>

<p class=MsoNormal style='margin-left:21.3pt;text-indent:-21.3pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='color:black'>2.       Calculate
the dose and the number of Armisarte vials needed. </span></p>

<p class=MsoNormal style='margin-left:21.3pt;text-indent:-21.3pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='color:black'>3.       Armisarte
</span><span lang=EN-GB>must only be diluted<span style='color:black'> with 5%&nbsp;glucose
solution, without preservative</span>. The appropriate volume of pemetrexed
concentrate must be diluted <span style='color:black'>to 100&nbsp;ml with 5%&nbsp;glucose
solution</span> and administered as an intravenous infusion over 10&nbsp;minutes.
</span></p>

<p class=MsoNormal style='margin-left:21.3pt;text-indent:-21.3pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='color:black'>4.       Pemetrexed
infusion solutions prepared as directed above are compatible with polyvinyl
chloride and polyolefin lined administration sets and infusion bags. Pemetrexed
is incompatible with diluents containing calcium, including lactated Ringers
Injection and Ringers Injection. </span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>Armisarte contains trometamol as an excipient. Trometamol
is incompatible with cisplatin resulting in degradation of cisplatin. This
medicinal product must not be mixed with other medicinal products. Intravenous
lines should be flushed after administration of Armisarte.</span></p>

<p class=MsoNormal style='margin-left:21.3pt;text-indent:-21.3pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='color:black'>5.       Parenteral
medicinal products should be inspected visually for particulate matter and
discolouration prior to administration. If particulate matter is observed, do
not administer.</span></p>

<p class=MsoNormal style='margin-left:21.3pt;text-indent:-21.3pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='color:black'>6.       Pemetrexed
solutions are for single use only. Any unused product or waste material should
be disposed of in accordance with local requirements.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB style='color:black'>Preparation and administration precautions</span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB style='color:black'>As with other potentially toxic anticancer
agents, care should be exercised in the handling and preparation of pemetrexed
infusion solutions. The use of gloves is recommended. If a pemetrexed solution
contacts the skin, wash the skin immediately and thoroughly with soap and
water. If pemetrexed solutions contact the mucous membranes, flush thoroughly
with water. Pemetrexed is not a vesicant. There is not a specific antidote for
extravasation of pemetrexed. There have been a few reported cases of pemetrexed
extravasation, which were not assessed as serious by the investigator.
Extravasation should be managed by local standard practice as with other
non-vesicants.</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;text-autospace:
none'><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB>Diluted solution</span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Chemical and physical in-use stability of infusion solution of
pemetrexed was demonstrated for 24&nbsp;hours at room temperature and 7&nbsp;days
at refrigerated temperature. From a microbiological point of view, the product
should be used immediately. If not used immediately, in-use storage times and
conditions prior to use are the responsibility of the user and would not be
longer than 24&nbsp;hours at 2&nbsp;°C-8&nbsp;°C, unless dilution has taken
place in controlled and validated aseptic conditions.</span></p>

<p class=MsoNormal style='margin-top:14.0pt;margin-right:5.95pt;margin-bottom:
11.0pt;margin-left:0in;line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

</div>

</body>

</html>
